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Wulin Jiang: Developing Induced Neural Stem Cell Therapy to Treat Triple-Negative Breast 
Cancer and Brain Metastases 
(Under the direction of Shawn Hingtgen) 
Triple-negative breast cancer (TNBC) is the most deadly subtype of breast cancer, with a 
high incidence of brain metastasis. With the absence of targetable molecules on the cell surface 
of the tumor, all of the currently available targeted cancer therapies become ineffective in 
treating TNBC, which makes the development of novel targeted therapies an urgent need. 
Induced neural stem cell (iNSC) has emerged as a promising targeted drug delivery platform 
attributing to its prominent tumor-homing property. Our previous study1 has reported the 
successful generation of human iNSCs from human fibroblasts using SOX2 single factor-
mediated cell reprogramming strategy, and has shown significant therapeutic effect of drug-
secreting hiNSCs in treating glioblastoma.  
In order to facilitate a broader application of hiNSC-based cancer therapy, in this 
dissertation, intravenously (IV) administrated hiNSCs secreting TNF--related apoptosis-
inducing ligand (TRAIL) to treat primary TNBC was investigated. While IV-infused hiNSCs 
demonstrated significant tumor-homing capability toward primary TNBC, hiNSC-TRAIL 
therapy also showed marked tumor-killing against primary TNBC in animal studies. 
To further improve this hiNSC-based drug delivery system, a second-generation iNSC, 
hiNeuroS, was developed using the same SOX2 single factor-based cell reprogramming strategy 
but a different cell generation process characterized by its sphere-based culturing system. In 
comparison with the first-generation hiNSCs, hiNeuroSs demonstrated a distinctive genetic 
 iv 
profile and significantly enhanced tumor-homing property toward TNBC brain parenchymal 
metastasis following intracerebroventricular (ICV) infusion. In addition, ICV-infused hiNeuroS-
TRAIL therapy demonstrated a remarkable therapeutic effect in treating both TNBC brain 
parenchymal metastasis and leptomeningeal carcinomatosis. 
Overall, these results indicate that our iNSC-based therapy has tremendous clinical 
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CHAPTER 1: INTRODUCTION 
1.1. TRIPLE-NEGATIVE BREAST CANCER 
1.1.1. CLINICAL SIGNIFICANCE 
Breast cancer is the most commonly diagnosed cancer type in US women and accounts 
for around 30% of female cancers with more than 270,000 estimated new cases in 2020.2 Based 
on tumor histological characteristics including estrogen receptor (ER) status, progesterone 
receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki67 index, 
breast cancer can be classified into five subtypes that are luminal A, luminal B HER2 -, luminal 
B HER2+, non-luminal HER2+, and basal. Wherein, basal subtype comprises the majority of 
triple-negative breast cancer (TNBC) cases.3,4  
TNBC is characterized by the absence of ER, PR, and HER2 receptor expression and 
represents about 15% of all breast cancer cases in the US.5 In comparison with other breast 
cancer subtypes, TNBC is the most aggressive subtype with the worst prognosis.6 Several 
clinical characterization studies have demonstrated that TNBC tends to have a younger patient 
group, higher mean tumor size, and higher-grade tumors.7,8 While the 5-year overall survival 
(OS) for all breast cancer patients is more than 90%, it is under 80% for patients with TNBC.9,10 
To better characterize TNBC-specific tumor heterogeneity, Lehmann et al. further defined 6 
TNBC subgroups based on tumor gene expression profile, which are basal-like 1 (BL1), basal-
like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like  (MSL), and 
luminal androgen receptor (LAR).11,12 Although the field is still debating around some of the 
definitions generated by this TNBC-specific tumor classification system, the attempt to further 
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stratify TNBC into more distinctive subtypes is definitely making a significant impact on the 
development of novel molecular driver-based targeted therapies.13,14 
 
1.1.2. CURRENT TREATMENT PARADIGMS AND CHALLENGES 
 Due to the absence of targetable tumor cell surface receptors, targeted therapies, such as 
endocrine therapies or anti-HER2 antibodies that are commonly used to treat ER+/PR+ or 
HER2+ breast cancer subtypes are ineffective in treating TNBC. And as a result, chemotherapy 
becomes the major systemic treatment option available to patients with TNBC on top of surgical 
resection and radiation therapy. The standard chemotherapy regimens for TNBC patients in 
either neoadjuvant or adjuvant setting usually comprises the combination of anthracyclines and 
taxane-based molecules.15 Depending on the patient’s response to these chemo-drugs and the 
progression of the disease, additional chemotherapy regimens, such as capecitabine, gemcitabine, 
or platinum-based chemo-drugs may be added.16  
 However, during the past several years, newly U.S. Food and Drug Administration 
(FDA)-approved novel targeted therapies have shed light on the redefinition of the treatment 
regimen for TNBC patients.  
 
1) Anti-PD-L1 monoclonal antibody: 
 In 2018, the Nobel Prize in Physiology or Medicine was awarded jointly to James P. 
Allison and Tasuku Honjo for their discovery of cancer therapy that suppresses negative 
immunomodulation.17 These phenomenal discoveries Dr. Allison and Dr. Honjo made have 
significantly benefited tens of thousands of patients with a variety of different cancers, which 
includes TNBC. In March 2019, FDA approved the first immunotherapy therapy for TNBC 
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patients, Tecentriq (atezolizumab), an anti-PD-L1 monoclonal antibody. This historical moment 
completely and dramatically changed the cancer treatment paradigm for TNBC patients.18  
 The immune checkpoint, programmed cell death protein 1 (PD-1) and programmed cell 
death protein 1 ligand (PD-L1) signaling pathway, is a cellular mechanism that is used to 
suppress the immune response and maintain immune tolerance under physiological conditions. 
However, it was found that tumor cells can hijack this immune mechanism by expressing PD-L1 
protein on the tumor cell surface to escape the anti-tumor immune response. Thanks to this 
discovery, during the past decade, numerous clinical studies have focused on the development of 
anti-PD-1/PD-L1 cancer therapies.19–21  
 The clinical study IMpassion130 (NCT02425891) initiated by Genentech was the first 
successful phase III clinical trial that evaluated the combination therapy of anti-PD-L1 
monoclonal antibody plus chemotherapy in treating untreated metastatic TNBC patients.22  In 
this study, the effect of atezolizumab plus nab-paclitaxel was investigated in comparison with 
nab-paclitaxel alone as a first-line therapy. For TNBC patients with positive PD-L1 expression 
(>= 1%), the addition of atezolizumab to nab-paclitaxel significantly improved median 
Progression-Free Survival (PFS) from 4.8 month to 7.4 months (HR 0.60; 95% CL, 0.48-0.77; 
p<0.0001), and in the meantime extended median OS from 15.5 months to 25 months (HR 0.62; 
95% Cl, 0.45-0.86).6,18,23  
 
2) PARP inhibitor: 
 BRAC1 and BRAC2 have been well-known cancer-related genes since their discovery in 
the 1990s. They are considered to function as “caretaker” genes as they involve in the 
maintenance of genomic integrity by participating in the DNA repair process during DNA 
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replication. Genetic disruption of BRAC1/2 in humans could lead to a natural susceptibility to 
breast and ovarian carcinomas.24,25 In breast cancer, 19.5% of TNBC patients have been shown 
to have germline BRAC mutations.26 
 For cells with BRAC mutations, many backup DNA repair mechanisms are activated and 
poly-ADP-ribose polymerase (PARP) is one of the key alternative responders to DNA strand 
breakage. Since PARP has been playing a critical role following DNA accidental breaks when 
the BRCA pathway is not available, it was found that PARP inhibition could lead to cell 
apoptosis through the accumulation of damaged DNA in the cells.27 
 By adopting this concept, the industry has been actively developing PARP inhibitor-
based cancer therapies during the past decade. And in 2018, FDA approved the first PARP 
inhibitor, Lynparza (olaparib) for the treatment of germline BRCA-mutated metastatic breast 
cancer developed by AstraZeneca. The phase III randomized study (OlympiAD NCT02000622) 
showed that PFS for patients treated with olaparib monotherapy was significantly extended by 
2.8 months compared to patients receiving standard chemotherapy (7.0 months vs. 4.2 months; 
HR 0.58). In the meantime, the response rate was also significantly higher in the olaparib group 
(59.9% vs. 28.8%). Despite these exciting results, unfortunately, no statistically significant 
improvement in OS was observed in the olaparib group.28 
 
3) Anti-Trop2 Antibody Drug Conjugate: 
Trophoblast cell surface antigen 2 (Trop-2), also known as epithelial glycoprotein-1 is a 
transmembrane glycoprotein that mediates a variety of cell signaling pathways including cell 
self-renewal, proliferation, and transformation.29 Given the importance of these key cell 
regulatory roles Trop-2 is playing, the overexpression of Trop-2 has been found to be linked to 
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the progression and metastasis of many human epithelial cancers, such as breast cancer, lung 
cancer, and colorectal cancer.30 In addition, one previous study reported that Trop-2 expression is 
substantially higher in HR+/HER2- breast cancer and TNBC in comparison with other breast 
cancer subtypes.31 Therefore, Trop-2 targeted therapy has become a promising strategy for solid 
tumor treatment. On April 22, 2020, FDA approved the first Trop-2 targeted antibody-drug 
conjugate (ADC), Sacituzumab Govitecan-hziy for the treatment of metastatic TNBC as a third-
line therapy.32 
Sacituzumab Govitecan-hziy (Trodelvy) is an anti-Trop-2 antibody conjugated to an 
active metabolite of irinotecan (SN-38) that inhibits the nuclear topoisomerase I enzyme 
resulting in double-strand DNA breaks and then cell death.33 In the phase III ASCENT trial 
(NCT02574455) sponsored by Gilead, 529 patients with metastatic TNBC with at least 2 lines of 
prior treatment were randomized to receive either sacituzumab govitecan-hziy or physician’s 
choice of single-agent chemotherapy. The result showed that patients treated with sacituzumab 
govitecan-hziy presented significantly improved PFS (5.6 months vs 1.7 months, HR: 0.41), OS 
(12.1 months vs 6.7 months, HR: 0.48), and overall response rate (35% vs 5%. P<0.0001) 
compared to the chemo group.34 
While these newly-FDA-approved therapies have shown remarkable efficacy in treating 
some TNBC patients, still, a large number of TNBC patients cannot benefit from those novel 
therapies due to the low expression level of PD-L1 on their tumor cells, or not carrying 




1.1.3. BRAIN METASTASES 
 Breast cancer represents the second-highest incidence of brain metastasis after lung cancer. 
While brain metastases occur in 10%-16% of advanced breast cancer patients35, the incidence of 
brain metastases significantly increases to as high as 46% among patients with advanced TNBC36. 
In comparison with other breast cancer subtypes, patients with TNBC brain metastases also have 
the worst prognosis. It was reported in several retrospective studies that the median OS after the 
development of brain metastases was shorter than 5 months for patients with TNBC, while that 
number was more than doubled in other subtypes.37,38 
 As of now, TNBC brain metastases treatment has remained extremely challenging for two 
major reasons. Firstly, similar to the primary TNBC, brain metastases tumor cells are also absent 
of targetable surface biomarkers, which results in the ineffectiveness of targeted therapies as 
previously mentioned. In addition, the existence of the blood-brain barrier (BBB) which tightly 
regulates molecules and cell transportation into and out of the central nervous system (CNS) makes 
systemic treatment even more difficult.39 To date, no systemic therapy has been FDA approved 
yet for treating TNBC brain metastases.40 The current standard of care (SOC) is limited to surgical 
resection, radiation therapy, and platinum or taxane-based chemotherapies. Depending on the 
number, distribution, and size of brain metastasis foci, stereotactic radiosurgery (SRS) or/and 
whole-brain radiotherapy (WBRT) will be applied.16 
 In recent years, with the emergence of novel targeted cancer treatment strategies, such as 
PARP inhibitor and immune checkpoint inhibitors as previously mentioned, their application in 
treating TNBC brain metastases is also being investigated in clinical settings. In a Phase II study 
(NCT02595905), the efficacy of the combination of cisplatin with a PARP inhibitor, veliparib was 
investigated in patients with metastatic TNBC, including patients with brain metastases, though 
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the result in TNBC brain metastases subpopulation has yet to be reported.39 In a Phase III study 
(NCT01945775), the efficacy of another PARP inhibitor, talazoparib was also evaluated in 
metastatic TNBC patients with a germline BRCA1/2 mutation. It was reported that among patients 
with brain metastases, PFS was significantly improved in the talazoparib group compared to the 
chemotherapy group (HR: 0.32).41 The in-depth analysis of the IMpassion130 study 
(NCT02425891) in which the efficacy of atezolizumab, a PD-L1 antibody plus nabpaclitaxel in 
treating advanced TNBC patients were assessed revealed that this combination therapy could also 
provide markedly clinical benefit to TNBC patients with brain metastases.23                                                   
Although patients with brain metastases have started being included in several clinical 
trials for the assessment of novel therapies on different patient subpopulations, their inclusion rate 
remains relatively low compared to patients with metastases to other tissues. In the meantime, 
clinical investigations that specifically target patients with brain metastases are still lacking.40,42 
To fully evaluate the efficacy of novel cancer treatment strategies in treating breast cancer patients 
with brain metastases, especially TNBC patients, not only more inclusion in different clinical 
studies but also clinical studies that primarily target breast-to-brain metastasis patients are highly 
desired. In addition, other than evaluating novel systemic therapies, novel strategies to maximize 
drug delivery to CNS by circuiting BBB is also urgently needed.  
 
1.2. STEM CELL-MEDIATED DRUG DELIVERY FOR CANCER TREATMENT 
 Stem cell-mediated drug delivery has been emerging as a promising strategy for cancer 
treatment. By leveraging its tumor tropism property, stem cells can effectively deliver 
therapeutic cargos to the targeted tumor region while minimizing its effect on normal tissues. 
Compared to common systemic therapies, such as chemotherapies, stem cell-mediated therapy 
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has a more sustained drug release profile particularly in the vicinity of the tumor, thereby 
potentiating its tumor-killing effect and minimizing the off-target effect of the therapeutic agents. 
Currently, mesenchymal stem cells (MSCs) and neural stem cells (NSCs) are the two stem cell 
types that have been most extensively studied as the drug delivery vehicle for cancer treatment.43          
                                                                                                                                                                                                                                                                                                         
1.2.1. STEM CELL TUMOR-HOMING PROPERTY 
As a novel and promising drug delivery system, the underlying mechanism of stem cell 
tumor tropism has been robustly investigated for the past 10 years. While the cellular and 
molecular mechanism of stem cell tumor tropism is far from being completely elucidated, 
numerous in vitro and in vivo studies have reported insightful observations, which have 
remarkably contributed to the full characterization of stem cell tumor tropism.43–46 
Chemoattractants secreted from tumor and tumor microenvironment that consists of 
stromal cells, infiltrating immune cells, and extracellular matrix have been considered as the 
major signal source that attracts stem cells to migrate to the tumor site.47,48 To date, stromal cell-
derived factor 1 (SDF-1, as known as CXCL12) is the best-studied chemokine that induces the 
migration of multiple stem cell types, such as hematopoietic stem cells (HSCs)49, MSCs50, 
NSCs51, induced pluripotent stem cells (iPSCs)52, and induced neural stem cells (iNSCs)1 by 
interacting with the chemokine receptor CXCR4 expressed on the stem cell surface. In addition 
to the SDF-1/CXCR4 signaling axis, it has been reported that CXCL16, CCL25, and IL6 were 
also identified chemokines that attract the migration of MSCs toward the tumor 
microenvironment.53–55. For NSCs, urokinase plasminogen activator (uPA)/urokinase 
plasminogen activator receptor (uPAR)56, vascular endothelial growth factor (VEGF)/vascular 
endothelial growth factor receptor 2 (VEGFR2)57, and hepatocyte growth factor 
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(HGF)/hepatocyte growth factor receptor (HGFR, also known as c-MET)58 signaling pathways 
have also been proved to play a significant role in stem cell tumor tropism. For example, one in 
vitro study showed that the depletion of uPA from prostate cancer cell-conditioned medium 
significantly inhibited the migration of NSCs, while the overexpression of uPA in neuroblastoma 
cells induced robust NSC migration toward tumor cells. 
Hypoxia is a critical aspect of the tumor microenvironment. The poor blood supply 
within the tumor microenvironment results in serial hypoxic responses initiated by the 
production of hypoxia-inducible factors (HIFs).59 It was shown in one study that the knockdown 
of HIF-1α in glioblastoma (GBM) cells markedly reduced their expression of SDF-1, uPA, and 
VEGF, and decreased NSC tumor tropic migration; In the meantime, the same study also showed 
that hypoxia led to the upregulation of CXCR4, uPAR, VEGFR2, and c-MET in NSCs, 
indicating that hypoxia plays a key role in mediating NSC tropic homing to brain cancers.51 
Besides, phosphoinositide 3-kinase (PI3K), a protein that is involved in a variety of cellular 
functions, has also been shown to regulate stem cell migration by serving as a convergence point 
for growth factor-based signals, such as HGF and VEGF.60,61 
 As more studies elucidated the underlying mechanism of stem cell tumor tropism, how to 
translate this knowledge into clinical application and impact becomes the next key step for 
improving stem cell-mediated therapies. Since it was reported that tumortropic receptors level on 
NSCs were upregulated under hypoxic conditions, one approach for enhancing stem cell tumor-
homing capability could be cell hypoxic preconditioning before administration. In addition, 
using genetic engineering to increase the expression level of target tumortropic receptors on stem 
cells could be another viable option.45 
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1.2.2. THERAPEUTIC PAYLOADS 
 By leveraging the tumor-homing property of stem cells, a variety of stem cell-mediated 
therapies has been developed and even tested in human clinical trials. Depending on the 
characteristics of the therapeutic agents secreted or released by the stem cells, stem cell-mediated 
therapies can be mainly categorized into three major groups which are 1) genetically modified 
stem cells; 2) nanoparticle-loaded stem cells; 3) oncolytic virus-loaded stem cells.43,46 
 
1) Genetically modified stem cells: 
With genetic modifications, stem cells can secret a wide variety of therapeutic agents,  
including enzymes, tumor-toxic proteins, and immune-modulating agents.  
The strategy in which stem cells secret enzymes to convert non-toxic prodrugs to 
cytotoxic active molecules is well-known as “suicide gene therapy” or “gene-directed enzyme 
prodrug therapy (CDEPT)”.62 In this strategy, circulating prodrugs will only be activated and 
converted to cytotoxic molecules surrounding the tumor area with the presence of enzyme-
secreting stem cells. Currently, there are three most commonly used suicide gene systems which 
are 1) cytosine deaminase (CD) that converts 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU), 
2) the herpes simplex virus thymidine kinase (HSV-TK) that converts ganciclovir (GCV) to 
GCV-monophosphate, which is further phosphorylated to GCV-triphosphate, and 3) 
carboxylesterase (CE) that converts irinotecan to its toxic metabolite SN-38.46 In preclinical 
studies, both MSC and NSC-based CD/5-FC systems have been proved effective in treating brain 
tumors, such as GBM63,64 and medulloblastoma65, while several studies showed the efficacy of 
HSV-TK/GCV stem cell system not only in brain tumor models66 but also in other peripheral 
solid tumor models, such as breast cancer67 and prostate cancer68. In addition, human NSCs with 
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CE/irinotecan system have also proved to be effective in ovarian69 and lung70 cancer models, as 
well as medulloblastoma71. In the clinic, several stem cell-based suicide gene therapies have 
been under evaluation at different stages. For example, a CD-expressing NSC/5-FC therapy is 
being assessed in recurrent high-grade gliomas patients (Phase I, ongoing, NCT02015819)43, and 
a Phase I/II trial on the assessment of HSV-TK expression MSC/ganciclovir therapy in advanced 
recurrent or metastatic gastrointestinal adenocarcinoma patients was completed in 2017 
(EudraCT 2012-003741-15)72. 
Engineering stem cells to secret tumor-toxic proteins that directly act on tumor cells is 
another popular strategy that has been widely employed in the development of stem cell-
mediated cancer therapies. Amongst different types of tumor-toxic proteins, TNF-α-related 
apoptosis-inducing ligand (TRAIL) is the most widely tested therapeutic agent against various 
tumors. When binding to death receptor 4 (DR4) and death receptor 5 (DR5) that are 
preferentially expressed on tumor cells, TRAIL induces cell apoptosis and thus results in tumor 
killing.73 Currently, there is a Phase I/II clinical trial investigating the effect of TRAIL-
expressing MSCs in patients with lung adenocarcinoma (NCT03298763, recruiting).43 Other than 
TRAIL, stem cells expressing biologic agents that block growth factor receptors, such as 
epidermal growth factor receptor (EGFR), to inhibit tumor proliferation have also shown to be 
effective on tumor inhibition in various preclinical models.74 
Tumor microenvironment modulation via stem cell-delivered immune-modulating agents 
to realize tumor suppression has been another cancer treatment strategy. The secretion of 
immunomodulatory molecules at the tumor site could reshape the tumor microenvironment from 
immunosuppressive to immune-responsive and thus redirect immune cells to fight against 
tumors.75 Human MSCs secreting IL-12 or IL-18 have been tested in mice bearing renal cell 
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carcinoma76, cervical tumors77, and glioma78,79. These studies reported that the sustained 
expression of ILs from stem cells at the tumor site had not only shifted the tumor 
microenvironment immune profile, including increased interferon-γ (IFN-γ) level, natural killer 
cells activation, and tumor-specific T-cells recruitment but also resulted in extended survival, 
suggesting the potential of this immune-modulation approach to fighting cancers.76–79 
 
2) Nanoparticle-loaded stem cells 
Nanoparticles (NPs) have been broadly investigated as drug delivery vehicles for the 
treatment of a variety of diseases. While NP-mediated drug delivery system possesses the 
advantages of incorporating water-insoluble therapeutic molecules, improving molecule stability 
in the blood circulation, and delivering the cargo in a targeted manner, its effectiveness against 
solid tumors and metastases is still considered suboptimal due to its relatively rapid clearance 
and inefficient tumor penetration.80 However, when combined with stem cells, it was found that 
NPs could better exert their tumor-killing function. In general, there are two commonly utilized 
methods to load stem cells with NPs.81 The first approach is to internalize NPs into the stem cells 
via either passive update or active endocytosis. One study reported that intravenous (IV) 
injection of MSCs loaded with paclitaxel-loaded NPs (PTX-NPs) led to more NP localization at 
the tumor site in the mice bearing orthotopic lung tumor, as well as significantly enhanced tumor 
growth inhibition and survival in comparison with PTX or PTX-NPs alone group.82 The second 
approach for NPs loading is to anchor the NPs on the stem cell surface via chemical conjugation. 
It was reported by Layek et al. that the NP-stem cell binding efficiency could be significantly 
improved by conjugating cyclooctyne-modified NPs with azide-functionalized MSCs.83 Another 
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study demonstrated remarkedly enhanced NPs delivery and anti-tumor effect from the 
conjugation of TRAIL-expressing MSCs and drug-loaded NPs.84 
 
3) Oncolytic virus-loaded stem cells 
Oncolytic virus possesses the ability to selectively replicate in tumor cells and then 
induce tumor lysis, which makes it a promising tumor-killing strategy. However, its in vivo 
efficacy against tumors is usually compromised due to its rapid clearance following systemic 
administration primarily mediated by host immune response.85 Stem cells have been explored as 
oncolytic virus delivery vehicles to improve oncolytic virus pharmacokinetics (PK) so that to 
enhance the therapeutic outcome of oncolytic virus-mediated cancer therapy. Stem cell-delivered 
oncolytic virus therapy has been investigated in various tumor models, such as hepatocellular 
carcinoma86, metastatic breast cancer87, and GBM88–90. For example, one study showed that 
human NSC-delivered oncolytic virus in combination with radiation and temozolomide could 
significantly enhance the survival of GBM-bearing mice.90 In another study, it was reported that 
MSCs loaded with oncolytic virus could significantly suppress the tumor growth in 
hepatocellular carcinoma model.86 
 
1.2.3. STEM CELL SOURCE 
Depending on the relationship between the source of the stem cells and the cell recipient, 
stem cell-based therapy can be classified into two subtypes, allogeneic therapy and autologous 
therapy. While autologous therapy means that the source of the cells and the therapy recipient is 
the same person, allogeneic therapy means the person who receives the therapy is not the original 
host of the stem cells.91 Compared to “off-the-shelf” allogeneic stem cells, autologous stem cell 
therapy is believed to have a longer persistence profile following cell administration due to its 
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low immunogenicity and minimized immune clearance92, which could potentially allow more 
stem cells to migrate toward the tumor for a longer time, leading to better therapeutic outcome in 
cancer treatment. Before 2006, endogenous stem cell is the sole source for autologous stem cell-
based therapy. However, since the most recent breakthrough of cell reprogramming technology 
reported by Dr. Shinya Yamanaka and his group in 2006, iPSCs and iNSCs have become another 
two promising autologous stem cell-based drug delivery system candidates for the treatment of 
cancers. Unlike endogenous stem cells that require complicated cell collection procedures, the 
development of iPSCs or iNSCs starts with easily obtained somatic cells, such as skin 
fibroblasts, and can be translated into rapid production in a scalable manner, making 
personalized cell therapy more attainable.93 
 
1.3. INDUCED NEURAL STEM CELLS 
  The generation of iNSCs based on the transdifferentiation of fibroblasts was firstly 
introduced by Kim et al. in 2011. While these iNSCs were characterized identical to endogenous 
NSCs based on their genetic profile (e.g. positive for typical NSC markers, such as PAX6 and 
SOX1), their production efficiency was significantly higher than endogenous NSCs which need 
to be isolated from primary tissues.94 In comparison with iPSCs harboring the risk of teratoma 
formation following administration in vivo, iNSCs have been proved to possess a higher level of 
safety profile, which has prompted numerous investigations into the development of more 
efficient and sustainable cell reprogramming strategies for the generation of iNSCs to advance 
iNSC-based therapies for different diseases treatment.95,96 
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1.3.1. CELL REPROGRAMMING STRATEGIES  
 Transducing somatic fibroblasts with viral vector encoding transcription factors is the 
most dominant cell reprogramming strategy for the generation of iNSCs. Depending on the 
combination of transcription factors utilized in the process, this strategy could be further divided 
into two main methods, namely indirect and direct reprogramming.97 
 Indirectly reprogramming, which relies on the employment of the classic Yamanaka 
reprogramming factors (OCT4, SOX2, KLF4, and c-MYC) with a modified culture method, was 
the first reported cell reprogramming strategy to produce iNSCs.94 By temporally controlling the 
overexpression of Yamanaka factors followed by the conditioning in a neural reprogramming 
medium that contains particular neural induction factors, the cell population that was in a non-
pluripotent unstable intermediate cell state was redirected to a neural stem cell fate. Thus, instead 
of becoming iPSCs, the cell population was induced to become iNSCs. Despite the success, the 
resultant iNSCs generated from this indirectly reprogramming strategy exhibited very limited 
cell proliferation and differentiation capability96,97, which pushed the development of iNSC 
reprogramming to the next stage, direct reprogramming.  
 Direct reprogramming tends to directly convert fibroblasts to iNSCs by circumventing 
the unstable intermediate cell state with the overexpression of neural stem cell lineage-specific 
transcription factors.97 In the first study adopting this concept reported by Lujian et al. in 2012, 
the combination of Brn2, FoxG1, and Sox2 was utilized to generate stably expandable iNSCs.98 
In the same year, Ring et al. reported another study in which they successfully generated iNSCs 
from both mouse and human fibroblasts by using only a single factor, SOX2.99 
 While numerous studies are focusing on the discovery of a more effective and efficient 
transcription factor combination to generate iNSCs, concerns are arising in regards to viral 
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vector-mediated gene integration that may cause cell mutagenesis.97 To minimize the risk of 
mutagenesis caused by exogenous random integration, researchers have started developing non-
viral cell reprogramming strategies.  
 Chemical reprogramming is deemed as one of the low-risk cell reprogramming strategies 
to generate iNSCs that requires no viral transduction and thereby represents a more clinically 
relevant approach. To date, several groups have achieved chemical-induced iNSC generation 
using different small molecule combinations.97 For example, in 2016, Zhang et al. successfully 
made the conversion of mouse embryonic fibroblasts (MEFs) into iNSCs with 24%-30% cell 
reprogramming efficacy and more than ten passages expansion capacity by introducing a  
cocktail of nine small molecules.100 
 CRISPR/Cas9-based gene-editing system has been widely adopted in the research of 
various life science domains amongst which including cell generation.101 Using the 
CRISPR/Cas9 system, the expression of endogenous fate-specifying genes can be activated, 
which leads to the reprogramming of somatic cells to target cell type. It was reported in one 
study that MEFs were successfully converted to induced neuronal cells through CRISPR/Cas9-
mediated activation of endogenous Brn2, Ascl1, and Myt1l genes, evidencing the possibility of 
using CRISPR-Cas9 system to generate iNSCs.102 
 MicroRNAs (miRNAs) are naturally occurring small non-coding RNAs that regulate 
gene expression by binding to a specific site of target mRNAs and in turn affect cellular 
behaviors.103 Several recent studies have identified miRNAs as key regulators in the process of 
neurogenesis, and in particular, it was found that miRNA-9 and miRNA-124 were involved in 
the promotion of NSC differentiation, while miRNA184 and miRNA-187 played a crucial role in 
NSC proliferation96,97,104. All these studies have laid a solid scientific foundation for the 
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development miRNA-mediated cell reprogramming strategies to convert somatic fibroblasts to 
iNSCs. By upregulating the expression of miRNA-9 and miRNA-124, one group has reported 
the successful conversion of human fibroblasts into neurons105, suggesting the potential of this 
strategy in iNSC generation.  
 
1.3.2. CHALLENGES FOR INSC APPLICATION IN CANCER TREATMENT 
Using human iNSCs (hiNSCs) as drug delivery vehicles for cancer treatment was firstly 
reported by Bagó et al. in 2017. In this study, a TRAIL or thymidine kinase (TK)-releasing 
hiNSC platform was developed to treat GBM.106 While new iNSC-based cancer therapies are 
being investigated, several challenges also need to be considered. 
NSCs by nature can differentiate into three major neural cell types that are neurons, 
astrocytes, and oligodendrocytes.107 While this capability is highly appreciated in the application 
of treating neurodegenerative diseases108, cell differentiation is undesired in the case of using 
NSCs as a drug delivery vehicle for cancer treatment, which also holds for iNSCs. In the study 
where iNSCs were co-implanted with GBM cells in mouse brains, Bagó et al. reported the 
presence of both NSC marker, Nestin, and neuron marker TUJ-1 in the iNSCs two weeks after 
cell implantation106, indicating a minor cell differentiation. Therefore, how to effectively 
maintain iNSCs in the undifferentiated state after cell administration to maximize therapeutic 
outcome remains one of the major challenges for iNSC-mediated cancer therapies.  
The key advantage of personalized cell therapy is its in-theory low immunogenicity that 
could minimize therapy immune rejection and prolong therapeutic effect. However, minimal 
epigenetic changes or genetic modifications during cell reprogramming could potentially lead to 
altered cell immunogenicity and reduced immune tolerance.109 It has been reported by Zhao et al. 
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that mouse iPSCs transdifferentiated from MEFs showed strong immune rejection following 
transplantation into C57BL/6 mice in comparison to mouse endogenous embryonic stem cells 
(ESCs).110 Although another study showed that MEF-derived mouse iNSCs via indirect cell 
reprogramming strategy elicited minimal immune response after implantation in syngeneic 
mouse brain111, the immune response against iNSC-based cancer therapies has yet been 
characterized by any preclinical or clinical studies, casting an urgent need for such an 
investigation to further advance iNSC-based cancer therapy into the clinic. 
 Inter-patient variation has always been a hurdle for the development of cancer therapies 
because various patient populations with differential genomic backgrounds may have completely 
different treatment responses.112 Therefore, how to develop and test a cancer therapy in the most 
relevant and representative model becomes a major challenge, and this challenge has only been 
more manifested in the case of personalized cell therapy. To develop iNSC-based therapies in the 
preclinical settings, established mouse or human fibroblast cell lines are usually utilized as the 
starting point for cell reprogramming.97 However, when the therapies are translated into the 
clinic, patient’s skin biopsies will be used as the starting material and the cell reprogramming 
efficiency on patient’s own skin cells may vary a lot from one to the other if universal cell 
reprogramming protocol is applied, which may in turn dramatically impact the overall 
therapeutic outcome. In one study, Buckley et al. characterized the cell reprogramming and 
engineering efficacy of generating TRAIL-releasing hiNSCs from 6 different cancer patients’ 
skin biopsies to treat GBM with a standard cell generation protocol. The results showed that each 
patient-specific hiNSC line presented a unique NSC-related gene expression profile, as well as 
differential tumor tropism and tumor-killing capability113, suggesting that a customized patient-
 19 
specific cell reprogramming strategy has to be incorporated into the development process for 
iNSC-based cancer therapies to ensure the maximal therapeutic effectiveness for every patient.   
 
1.4. SCOPE AND AIMS 
Previous studies have demonstrated the potential and advantages of using iNSCs as a 
therapeutic tool for treating various diseases. While iNSC-mediated therapies have been 
extensively studied in the treatment of neurological disorders, such as spinal cord injury114, 
stroke115, and Parkinson’s disease116, its application in cancer treatment has yet been fully 
explored. To date, our lab is the only group that reported the application of utilizing drug-loaded 
hiNSCs to treat GBM.1 For the remaining of this work, the application of hiNSC-based therapy 
in treating primary TNBC and breast-to-brain metastasis was investigated. In addition, a second-
generation iNSCs, hiNeuroS, was developed and its therapeutic effect was evaluated in TNBC 
brain metastasis models.  
 
1.4.1 AIM 1: INVESTIGATE HINSC THERAPY TO TREAT PRIMARY TNBC 
 In aim 1, the migratory capability and therapeutic effect of intravenously (IV) infused 
hiNSCs were assessed in an orthotopic TNBC model. In addition, the safety and toxicity of 
hiNSC-based therapy following IV injection were investigated.  
 
1.4.2 AIM 2: DEVELOP SECOND-GENERATION INSC THERAPY FOR TREATING 
TNBC BRAIN METASTASES  
 In aim 2, a new version of iNSC, hiNeuroS, with enhanced tumor-homing capability and 
genetic profile was developed and characterized. The migratory capability and therapeutic effect 
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of intracerebroventricularly (ICV)-delivered hiNeuroSs were evaluated in TNBC brain 





CHAPTER 2: CYTOTOXIC ENGINEERED INDUCED NEURAL STEM CELLS AS 
INTRAVENOUS THERAPY FOR PRIMARY NON-SMALL CELL LUNG CANCER 
AND TRIPLE-NEGATIVE BREAST CANCER1 
2.1 INTRODUCTION 
Lung and breast cancer are the most common forms of cancer in the United States, 
together accounting for an estimated 29% of all new cancer cases diagnosed in 2018; these 
cancers are among the deadliest, accounting for nearly 1/3 of all cancer deaths.117 There remains 
a significant need for more effective systemic treatments to improve the care for patients 
suffering from these cancers. Emerging data suggests cell therapies may represent a novel and 
effective new treatment option.  
Neural stem cells (NSCs) have emerged as promising anti-cancer drug delivery vehicles 
due to their innate tumor tropism.45,65,70,118–120 Several studies have shown genetically engineered 
NSCs home selectively to brain cancer, allowing them to deliver anti-cancer gene products 
directly to local and distant tumor foci, significantly reducing tumor volumes and markedly 
extending survival.64,65,118,121,122 Not limited to the brain, new studies have demonstrated that 
intravenously infused tumoricidal NSCs extravasate from vessels to populate tumor foci and 
significantly reduce human cancer in orthotopic mouse models of breast cancer, lung cancer, and 
a variety of other tumor types.64,65,70,118,120–123 These studies demonstrate the potential of tumor-
 
1 Chapter was adapted from an article under review at Molecular Cancer Therapeutics. The original citation is as 
follows: Mercer-Smith, A.R., Jiang, W., Bagó, J.R., Valdivia, Woodell, A.S., Montgomery, S.A., Sheets, K.T., 
Anders, C.K., Hingtgen, S.D. “Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for 
Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics. (Under 
revision). A.R. Mercer-Smith and W. Jiang are co-first authors. 
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homing NSC therapy for the treatment of aggressive extracranial cancers; as these treatments 
move forward, the ideal source of NSCs remains in question. 
Selecting the most effective NSC carrier will be critical to maximizing persistence, tumor 
targeting, and ultimately tumor kill in human patient trials. Allogeneic NSCs have shown success 
in preclinical testing64,123–126 and safety in early-stage human clinical trials for gliomas.118,121,127 
However, the high potential of allogeneic stem cell transplants for immune-mediated rejection128 
is likely to limit their residence time at tumors and ability to deliver therapeutic agents directly to 
peripheral cancer foci. In contrast, personalized NSC therapy holds the potential to avoid rapid 
immune clearance.128 This holds the potential to maximize treatment response in patients 
increasing the cell carriers that reach tumor foci, increasing cell carrier residence time, and 
delivering a more durable exposure for the therapeutic window to induce tumor kill. We recently 
discovered that transdifferentiation, a process that directly converts somatic cells into other adult 
cell types, can be used to generate tumor-homing drug carriers that regress tumor xenografts, 
known as human induced NSC (hiNSC).1,129 Using SOX2 as a single transcriptional factor, we 
transformed human fibroblasts into hiNSCs within one week of culture;1 we have shown this 
process is effective in transdifferentiating patient fibroblasts to be used in the treatment of 
patient-derived intracranial tumors.130 While the fibroblasts show random movement, the hiNSCs 
following transdifferentiation show significant directional migration to a tumor.1 The hiNSCs 
express NSC markers SOX2 and nestin and the neuronal marker TUJ-1 with minimal expression 
of the astrocyte marker GFAP or pluripotency markers NANOG or OCT4.1 In vivo, hiNSCs 
maintained expression of NSC marker nestin while expression of neuronal markers or 
pluripotency markers was virtually absent.17,130 In the clinic, hiNSC therapy will be a patient-
specific approach. In a recent study, we utilized canine models to demonstrate the feasibility of 
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autologous iNSC generation and implantation on a scale that more closely mirrors human 
patients.131 The migratory hiNSCs are also genetically engineered to secrete cytotoxic proteins 
such as tumor necrosis factor-α apoptosis inducing ligand (hiNSC-TRAIL), enabling the cells to 
track down and kill infiltrating cancer cells after infusion. While one initial study tested the 
ability of NSCs to reduce peripheral tumor burden in lung cancer,119 the therapeutic potential of 
hiNSCs for orthotopic breast and lung tumors has not yet been fully explored, despite the 
prevalence of these diseases. Moreover, no studies have investigated the efficacy of hiNSCs 
administered intravenously, a much less invasive technique where the ease of infusion and 
redosing provides significant clinical advantages over intratumoral injections. 
Herein we provide the first investigation into the intravenous infusion of rapidly 
transdifferentiated hiNSCs for the treatment of primary lung and breast cancer. Utilizing kinetic 
bioluminescence imaging, we show hiNSCs migrate rapidly to both human triple-negative breast 
cancer (TNBC) and non-small cell lung cancer (NSCLC) in co-culture assays. Furthermore, 
intravenously infused hiNSCs populated both tumor types in orthotopically-established mouse 
models of cancer and persisted at the tumor site for 14 days post-infusion. Exploring the anti-
tumor efficacy of hiNSC therapy, we show that hiNSC-TRAIL induced dose-dependent killing 
in co-culture assays. In vivo, serial bioluminescence imaging showed that intravenous hiNSC-
TRAIL therapy reduced tumor burden while extensive toxicity testing showed the treatment did 
not induce marked toxicity to healthy tissue. Overall, these results suggest intravenously infused 




2.2.1 ASSESSING HINSC MIGRATION TOWARD LUNG CANCER AND BREAST 
CANCER IN VITRO 
One of the most unique and beneficial attributes of hiNSC therapy is the ability of the 
cells to actively seek out and populate local and distant tumors. This ability has been proven 
extensively in mouse models of brain cancer where hiNSC are directly infused into brain tissue.1 
However, it is unknown whether SOX2-expressing hiNSCs (Appendix A.1) exhibit similar 
homing capability to extracranial tumors or whether their tumor-homing capacity remains intact 
when infused intravenously into the bloodstream. To answer these questions, we first 
investigated the tumoritropic properties of hiNSCs to TNBC and NSCLC cells using our mixed 
culture models where hiNSC migration is tracked in real-time. hiNSC-mC-FLuc cells were 
seeded 500 μm apart from A549-GFP-FLuc lung human cancer cells or MDA-MB231-Br-GFP-
FLuc human TNBC cells in two-chamber cell culture inserts (Fig. 2.1A). 24 hrs after seeding, 
the culture inserts were removed and kinetic high-resolution images were captured every 2 hours 
for 96 hrs to track the movement of hiNSC towards the cancer cells. Analysis of time-lapse 
images shows that hiNSCs directionally migrated towards both A549 and MDA-MB231-Br cells 
(Fig. 2.1B). Quantification further supported kinetic imaging results, showing a mean of 14 and 
29 cells migrated past a starting line designated by the leading edge of the hiNSCs at time 0 
towards A549 and MDA-MB231-Br, respectively, at 96 hrs compared to an average of only 3 
cells in control wells where hiNSCs were plated without nearby tumor cells (Fig. 2.1C). Single 
cell migratory path analysis of directionality showed the mean directionality index was 0.300  
0.016 and 0.352  0.022 for migrating hiNSCs towards A549 and MDA-MB231-Br compared to 
0.166  0.017 in control wells. The hiNSCs seeded adjacent to either A549 or MDA-MB231-Br 
showed farther mean final cell displacement (180  11 or 205  14 μm, respectively) than 
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hiNSCs seeded without nearby tumor cells (112  13 μm) (Fig. 2.1, D to F). These data suggest 
hiNSCs show directional movement toward TNBC and NSCLC cell lines. 
 
Figure 2.1. In vitro migration of hiNSC toward tumor cells. (A) Schematic of two-chamber wells to observe 
migration of hiNSCs (left) and tumor cells (right). (B) Fluorescent image of movement of hiNSCs (red) after 0 and 
96 hours, adjacent to tumors cells A549 or MDA-MB231-Br (green) or nothing (control). The white dotted line 
indicates position of hiNSCs at time 0. The red dotted line indicates the position of hiNSCs after 96 hours. Inset 
scale bar = 100 μm. (C) Number of hiNSCs that showed migration over time when plated adjacent to nothing 
(control), MDA-MB231-Br, or A549. **P<0.01 by Dunnett's post-hoc test. Data presented as mean +/- SEM. 
Significance values represent experimental group comparisons to controls. N = 6 for A549-GFP-NLuc, and N = 4 
for MDA-MB231-Br-GFP-NLuc. (D) Movement plots of hiNSCs movement when plated opposite nothing 
(control), A549, or MDA-MB231-Br. Each line indicates an individual cell's movement. (E) Violin plot indicating 
directionality of hiNSC movement toward nothing (control), A549, or MDA-MB231-Br. ****P<0.0001 by 
Dunnett's post-hoc test. (F) Violin plot indicating final displacement of hiNSC movement toward nothing (control), 
MDA-MB231-Br, or A549. ***P<0.001, ****P<0.0001 by Dunnett's post-hoc test with mean indicated by the red 
dot and SEM indicated by the red line. Unless otherwise specified, comparisons are not significant. Study analyzed 
by Alex Woodell. 
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2.2.2 INVESTIGATING HINSC MIGRATION TOWARDS NSCLC AND TNBC 
TUMORS IN VIVO 
In human patients, the majority of cell therapies are infused intravenously for the 
treatment of peripheral tumor types.132 As we found hiNSCs migrate to both TNBC and NSCLC 
in co-cultures, we sought to explore the ability of hiNSCs to target both tumor types in vivo 
following intravenous infusion and determine the residence time of the cells at the tumor. We 
first established either A549-GFP-NLuc orthotopic lung tumors or MDA-MB231-Br-GFP-NLuc 
fat pad tumors in athymic nude mice (Fig. 2.2, A and B). Once tumor establishment was 
confirmed by serial imaging, 1 × 106 hiNSC-mC-FLuc cells were administered intravenously 
into tumor-bearing mice, and hiNSC distribution was monitored by firefly luciferase BLI. In 
animals with orthotopic lung cancer xenografts, analysis of BLI signal showed hiNSCs were 
detectable at tumor foci in the thorax shortly after infusion. Thoracic BLI signal gradually 
declined over 11 days in mice both with and without tumors (Fig. 2.2C, Appendix A.2). To 
visualize hiNSCs at levels below the limit of detection by BLI, we performed fluorescent 
microscopic analysis of tissue sections from a subset of mice sacrificed at each time point. Our 
high-resolution imaging showed hiNSC-mC-FLuc were present and co-localized with GFP+ 
tumor within 3 days post-injection for A549 could still be detected 14 days post-infusion (Fig. 
2.2, C and E). In mice bearing TNBC tumors, the fluorescent analysis showed hiNSCs were 
detected at the tumor by day 3, reached peak accumulation peaking at day 7, and gradually 
declined through day 14 (Fig. 2.2, D and F). Fluorescent analysis was used to characterize the 
migration of hiNSCs toward TNBC tumors because the BLI signal of these cells was below the 
limit of detection. In both tumor models, hiNSCs were observed to colocalize to tumors within 3 
days and persisted for at least 14 days. 
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Figure 2.2. Migration studies of hiNSCs in vivo. (A-B) Schematic of in vivo workflow, where mice are implanted 
with tumors, infused with hiNSCs intravenously, and tumors are removed and sectioned for analysis. (C) 
Bioluminescence signal from hiNSC-mC-FLuc cells in the thoraces of mice with and without A549-GFP tumors. 
Mean luminescent background was 8.11 × 104 p/s. (D) hiNSC-mC-FLuc fluorescence intensity in MDA-MB231-Br-
GFP fat pad tumor sections. (E) Fluorescent images of sections of lungs with A549-GFP tumors. (F) Fluorescent 
images of sections of MDA-MB231-Br-GFP tumors. Scale bar = 50 μm. Data presented as mean +/- SEM. N = 5 for 
mice with A549-GFP tumor, and N = 3 for mice with MDA-MB231-Br-GFP tumors. Alison Mercer-Smith 
completed the studies involving the NSCLC line. 
 
2.2.3 EXPLORING THE EFFICACY OF INTRAVENOUS HINSC THERAPY FOR 
LUNG AND BREAST CANCER IN VITRO 
To take advantage of the hiNSCs’ tumor-homing migratory capabilities, we produced a 
line of hiNSC-TRAIL to test the ability of hiNSCs to deliver therapeutics to tumors. We 
performed co-culture assays with ratios ranging from 10:1 to 1:5 of tumor cells (NSCLC H460 
or TNB MDA-MB231-Br) to hiNSC-TRAIL cells for up to 7 days (Fig. 2.3A). Cell viability 
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assays and summary graphs showed hiNSC-TRAIL cells significantly reduced both H460 and 
MDA-MB231-Br tumor cells in a dose- and time-dependent manner. Viability as a percentage of 
control is presented in Fig. 2.3, B and C, and raw luminescent values are presented in Appendix 
A.3. To next investigate the kinetics of the tumor-killing by hiNSC-TRAIL, we performed real-
time serial imaging of tumor cell viability when incubated with hiNSC-TRAIL cells (Fig. 2.3, D 
to G). Analysis of kinetic killing curves showed a left-shift in the curve with increasing 
concentrations of hiNSC-TRAIL cells for both tumor cell lines, indicating tumor killing in a 
rapid and dose-dependent manner. At a 1:1 ratio of tumor:hiNSC-TRAIL, we found the therapy 
required 42 and 18 hours to induce 50% reduction in viability of H460 and MDA-MB231-Br, 
respectively. Despite initial differences in the rate of tumor kill, fluorescent images captured 96 
hrs post-treatment showed hiNSC-TRAIL therapy was able to reduce viability >98% relative to 
non-treated cells at the highest dose. Taken together, these data suggest hiNSC-TRAIL therapy 
induces killing of both TNBC and NSCLC cells. Importantly, decreasing the tumor:hiNSC-
TRAIL ratio not only increased the percentage of tumor cells killed, but also the rate at which the 
tumor cells died.  
 
2.2.4 INVESTIGATING HINSC THERAPY FOR NSCLC AND TNBC IN VIVO 
To investigate the efficacy of intravenous hiNSC therapy for lung and breast cancer, we 
tested the efficacy of hiNSC-TRAIL therapy against primary NSCLC and TNBC in vivo. 
Orthotopic H460-mCh-FLuc or MDA-MB231-Br-mC-FLuc tumors were established in the lungs 
or fat pad of nude mice, respectively. One week after tumor implant, 1× 106 hiNSC-TRAIL cells 




Figure 2.3. hiNSC in vitro killing against H460 and MDA-MB231-Br. (A) Schematic of workflow to assess 
viability of mC-FLuc cancer cells when co-cultured with hiNSC-TRAIL cells. (B) Fold change in luminescent 
signal of H460-mC-FLuc when exposed to different ratios of H460:hiNSC-TRAIL over 7 days, compared to each 
day's tumor-only signal. **P<0.01, ***P<0.001, ****P<0.0001 by one-way ANOVA, followed by Dunnett's post-
hoc test. N = 4. (C) Fold change in luminescent signal of MDA-MB231-Br-mC-FLuc when exposed to different 
ratios of MDA-MB231-Br:hiNSC-TRAIL over 3 days, compared to each day's tumor-only signal. ****P<0.0001 by 
Dunnett's post-hoc test. N = 8. Unless otherwise specified, comparisons are not significant. (D) Kinetic killing assay 
of H460 cells co-cultured with varying ratios of H460:hiNSC-TRAIL cells. N = 4. (E) Kinetic killing assay of 
MDA-MB231-Br cells co-cultured with varying concentrations of varying ratios of MDA-MB231-Br:hiNSC-
TRAIL cells. (F) Fluorescent images showing changes in H460-mC-FLuc survival following co-culture with 
different concentrations of hiNSC-TRAIL over 7 days. Scale bar = 200 μm. Inset scale bar = 100 μm. N = 4. (G) 
Fluorescent images showing changes in MDA-MB231-Br-mC survival following co-culture with different 
concentrations of hiNSC-TRAIL over 3 days. Scale bar = 200 μm. Inset scale bar = 100 μm.  
mice bearing orthotopic H460 tumors established in the lungs, intravenous hiNSC-TRAIL 
therapy reduced mean tumor volumes to 29.8% of the volumes of control-treated animals 14 
days post-treatment. Mice treated with hiNSC-TRAIL showed a reduction in tumor volume by 
day 14 after the first dose of intravenous hiNSCs (Fig. 2.4, C and E). The highly aggressive 
nature of this model led to rapid tumor rebound, though we did observe a modest trend toward 
improvement in overall median survival (39 days with 95% CI 31 – 46 days for mice treated 
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with hiNSC-TRAIL; 31.5 days with 95% CI 25 - 58 days for control mice) (Fig. 2.4G). hiNSC-
TRAIL therapy induced strong tumor kill in TNBC tumors (Fig. 2.4, D and F). Serial imaging 
showed mice with human TNBC infused with hiNSC-TRAIL therapy had a mean tumor volume 
of 20.1% and 7.3% compared to control-treated animals 14 days and 36 days post-treatment, 
respectively. For both tumor models, we observed significant reductions in tumor volumes in 
mice treated with intravenous hiNSC-TRAIL based on multiple unpaired t-tests without 
correction for multiple comparisons. Given the large number of time points, when a two-stage 
setup was used to correct for multiple comparisons, the adjusted P-values were >0.05. A strong 
though non-significant trend toward increased median survival was observed (100 days with 
95% CI 64 – 100 days for mice treated with hiNSC-TRAIL; 44 days with 95% CI 44 – 100 days 
for control mice) (Fig. 2.4H). 
 
2.2.5 HINSC AND TRAIL TOXICITY 
In order to determine the safety of hiNSC therapy, we had previously characterized both 
immortalized fibroblasts1 and non-immortalized patient fibroblasts,130 in which we observed no 
oncolytic transformation. To further investigate the safety of hiNSC therapy, we infused the 
single maximum tolerated dose of either non-therapeutic hiNSC-mC-FLuc or therapeutic hiNSC-
TRAIL to evaluate the impact of both the cell carriers and the carrier + drug, respectively. On 
subsequent days over a 28-day time-course post-infusion, lung, kidney, liver, and spleen were 
harvested, and histology, hematology, and blood chemistry values were evaluated and compared 
to blank, non-infused mice. H&E histochemistry of major organs demonstrated all examined 
organs were within normal limits regardless of whether the mice received the carrier + drug or 
the carrier alone. Rare, scattered cell clusters with large nuclei were identified within alveolar 
septal walls of lungs harvested from early time points in the post-infusion and carrier + drug  
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Figure 2.4. Therapeutic efficacy of hiNSC-TRAIL cells against H460 and MDA-MB231-Br in vivo. (A-B) 
Schematic of workflow, establishing tumors and intravenously infusing hiNSC-TRAIL cells. (C) Representative 
BLI in photons/sec (p/s) for mice with H460-mC-FLuc orthotopic lung tumors treated with control (hiNSC-GFP) 
and therapeutic (hiNSC-TRAIL) cells. (D) Representative BLI for mice with MDA-MB231-Br-mC-FLuc fat pad 
tumors infused with hiNSC-GFP or therapeutic hiNSC-TRAIL cells. (E) Mean H460-mC-FLuc BLI in mice with 
lung tumors treated with control (hiNSC-GFP) and therapeutic (hiNSC-TRAIL) cells. N = 15 for controls, and N = 
16 for mice treated with hiNSC-TRAIL. *P<0.05 by the unpaired multiple t-test without correction for multiple 
comparisons. (F) Mean MDA-MB231-Br BLI in mice infused with hiNSC-GFP or therapeutic hiNSC-TRAIL cells. 
N = 4 for control mice, and N = 5 for mice treated with hiNSC-TRAIL. *P<0.05 by the unpaired multiple t-test 
without correction for multiple comparisons. Unless otherwise specified, comparisons are not significant. Data 
presented as mean +/- SEM. Survival curve for mice with (G) H460-mC-FLuc orthotopic tumors or (H) MDA-
MB231-BR tumors treated with control (hiNSC-GFP) or therapeutic hiNSC-TRAIL cells. Studies using NSCLC 
lines were conducted by Alison Mercer-Smith. 
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groups; these are presumed to be the infused hiNSCs. The cell clusters were no longer observed 
in either Day 28 sample. Non-specific lymphocytic infiltration in liver samples was moderately 
increased in hiNSC-infused mice compared to blank, non-infused mice. Spleen samples in both 
groups showed moderately increased follicle size with occasional formation of germinal centers 
at each time point with the most activity seen in mice 3 days after infusion with the carrier. We 
speculate that hepatic lymphocytic and splenic responses are likely due to murine immune 
responses against human hiNSC infusion. Minimal interstitial nephritis was occasionally 
observed in the kidneys of mice infused with the carrier (Fig. 2.5, A to C). Hematology and 
blood chemistry values showed no significant sustained alterations in hiNSC-infused mice 
compared to blank mice (Table 2.1, Table 2.2). Mice infused with carrier only showed mild, 
transient increases in creatinine that resolved within 28 days of infusion. Minor transient 
decreases in BUN and creatinine were observed in mice infused with carrier + drug that each 
resolved. Taken together, the pathology, hematology, and clinical chemistry values indicate no 
significant toxic effects of either carrier or carrier + drug following intravenous infusion. TRAIL 
itself is only toxic to hiNSCs at concentrations (Appendix A.5) well above those achieved 
through production by hiNSCs, about 2 fg TRAIL/cell/hr.130 
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Figure 2.5. Safety of intravenously-infused carrier (hiNSC-mC-FLuc) or carrier + drug (hiNSC-TRAIL). 
H&E staining of lungs (Ai, Bi, Bii, Ci, Cii), kidneys (Aii, Biii, Biv, Ciii, Civ), livers (Aiii, Bv, Bvi, Cv, Cvi), and 
spleens (Aiv, Bvii, Bviii, Cvii, Cviii) of (A) non-tumor bearing, non-infused mice and (B) non-tumor bearing mice 3 
and 28 days after infusion of 1 × 106 hiNSC-mC-FLuc cells or (C) 1 × 106 hiNSC-TRAIL cells. The arrow in (Bi) 
indicates scattered cell clusters within the alveolar septal walls. Minor interstitial nephritis is indicated by arrows in 
(Biii). Lymphocytic infiltration is observed in (Aiii, Bv, Bvi, Cv, Cvi). Arrows in (Bvii, Bviii, Cvii, Cviii) indicate 







Table 2.1. Hematology and clinical chemistry values after hiNSC-mC-FLuc infusion 
  hiNSC-mC-FLuc 
 Blank Day 3 Day 7 Day 14 Day 28 
 Mean Low High Mean SEM Mean SEM Mean SEM Mean SEM 
Hematology            
Red blood cells (106/µl) 8.56 6.11 9.53 9.2 0.1 8.78 0.19 8.49 0.09 9.68 0.16 
White blood cells (103/µl) 2.64 0.42 7.49 0.77 0.3 0.57 0.22 1.58 0.51 6.62 1.07 
Neutrophils (%) 36.12 22.9 60.5 42.73 7.2 42.1 5.47 22.05 3.35 30.2 7.14 
Lymphocytes (%) 58.75 37.3 73.6 54.4 7.96 53.17 5.93 74.85 3.65 66.53 7.12 
Monocytes (%) 2.89 0.5 14.3 2.43 0.96 3.37 1.81 1.9 0 1.23 0.13 
Eosinophils (%) 1.86 0.8 2.8 0.3 0.3 0.7 0.7 0.5 0.5 1.95 0.23 
Clinical Chemistry            
Albumin (g/dL) 2.9 2.2 3.2 3.08 0.09 2.9 0.06 2.35 0.55 3.05 0.06 
BUN (mg/dL) 19.95 15 26 24 1 20 1 20.5 1.5 19.75 1.18 
Creatinine (mg/dL) 0.32 0.17 0.5 1.18 0.07 1.21 0.29 1.08 0.07 0.33 0.02 
ALT (U/L) 19.5 11 38 7.75 2.17 9.33 2.33 11.5 0.5 12.75 2.06 
AST (U/L) 87.5 39 302 155.25 49 100.67 12.91 169 96 48.25 3.33 








Table 2.2. Hematology and clinical chemistry values after hiNSC-TRAIL infusion 
  hiNSC-TRAIL 
 Blank Day 3 Day 7 Day 14 Day 28 
 Mean Low High Mean SEM Mean SEM Mean SEM Mean SEM 
Hematology            
Red blood cells (106/µl) 8.56 6.11 9.53 9.28 0.18 8.83 0.32 8.27 0.47 9.05 0.24 
White blood cells (103/µl) 2.64 0.42 7.49 6.31 1.13 3.84 0.89 1.77 0.3 1.01 0.12 
Neutrophils (%) 36.12 22.9 60.5 18.43 2.81 40.13 7.31 41.1 7.19 42.3 4 
Lymphocytes (%) 58.75 37.3 73.6 78.27 2.99 52.4 7.87 52.9 6.26 52.98 4.68 
Monocytes (%) 2.89 0.5 14.3 1.57 0.13 5.5 1.06 4.55 1.85 2.8 0.64 
Eosinophils (%) 1.86 0.8 2.8 1.7 0.35 1.7 0.25 1.25 0.3 1.73 0.38 
Clinical Chemistry            
Albumin (g/dL) 2.9 2.2 3.2 3.03 0.03 2.98 0.11 2.93 0.03 2.88 0.08 
BUN (mg/dL) 19.95 15 26 12.75 0.48 23.5 1.94 25 0.71 16.5 0.96 
Creatinine (mg/dL) 0.32 0.17 0.5 0.29 0.04 0.29 0.03 0.1 0.03 0.34 0.03 
ALT (U/L) 19.5 11 38 14.25 3.28 26.25 3.45 16.75 0.63 20.75 1.11 
AST (U/L) 87.5 39 302 110.75 42.85 100.75 3.01 64.75 2.5 170.25 10.42 





In this study, we investigated the ability of human fibroblasts that were rapidly 
transdifferentiated into hiNSCs to home to and kill primary NSCLC or TNBC tumors following 
intravenous infusion. While previous studies have investigated the use of hiNSCs to treat 
glioblastoma1,129 or other types of stem cells to treat extracranial tumors119,133–135, to our 
knowledge, this study marks the first effort to treat primary breast or lung tumors with hiNSCs. 
Migration of hiNSCs has been well-characterized in the brain parenchyma129,136, but this is the 
first study to investigate the distribution of intravenously administered hiNSCs. Our in vitro 
results show directional migration of hiNSCs toward both TNBC and NSCLC. Given that 
minimal and non-directional migration was observed in the control group, we infer the migration 
observed toward the cancer lines was not merely random motion or cell proliferation. hiNSCs are 
thought to follow chemokine gradients produced by tumor cells or surrounding areas of 
hypoxia,120 and we expected that an increasing number of hiNSCs would migrate toward cancer 
cells as the chemokine gradient is produced over time. While the number of migrating cells 
toward NSCLC was not significantly different between the control and treatment groups, 
significantly more hiNSCs migrated toward TNBC cells than controls, and the number of 
migrating hiNSCs toward tumor cells trended toward an increase over time to tumors. However, 
counting cells that pass the starting line discounts movement of cells that start far from the 
starting line. To account for differences in starting position, we also report directionality and 
displacement. We observed significantly increased directionality indices and final displacements 
of hiNSCs toward both tumor lines than in the control group, suggesting hiNSCs do migrate to 
both NSCLC and TNBC in vitro. To determine if these in vitro results translate to an in vivo 
setting, we tested the migration of hiNSCs to TNBC fat pad tumors or NSCLC lung tumors. We 
observed co-localization of hiNSCs at both NSCLC and TNBC tumor foci as early as 3 days and 
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as late as 14 days after intravenous infusion. This suggests the cells not only migrate to tumors 
quickly but also persist, albeit at low levels, for a relatively long period of time. These 
persistence results are consistent with our previous studies of hiNSCs in the brains of mice,1 and 
an autologous infusion of iNSCs likely would increase persistence even more, as our canine 
iNSC study showed persistence for more than 80 days.131 Importantly, our results here also 
suggest the migratory ability of hiNSCs is not limited by a specific tumor line as we observed 
migration toward both NSCLC and TNBC cells. These results indicate the versatility of these 
therapeutic hiNSCs target a variety of primary tumors extracranially.  
Our in vitro co-culture killing assay demonstrated that both NSCLC and TNBC cell lines 
are sensitive to cytotoxic TRAIL. TRAIL has been shown to increase the activity of caspase 3 
and 9 as well as annexin V and PI in tumor lines such as the NSCLC line H460.137 However, the 
TNBC line was much more sensitive to TRAIL than the NSCLC line. Differential TRAIL 
resistance for various tumor lines has been widely documented,138–142 and so partial resistance to 
TRAIL is not unexpected. Thus, in the proceeding experiments, we anticipated that the TNBC 
line would respond better to hiNSC-TRAIL than the NSCLC line. Despite the partial sensitivity 
to TRAIL observed in our in vitro studies and the highly invasive nature of the NSCLC line, the 
NSCLC tumors in vivo did respond well to hiNSC-TRAIL therapy. Both the mice with TNBC 
tumors and those with NSCLC that were treated with hiNSC-TRAIL therapy did show a 
reduction in the tumor BLI signal within 2 weeks of the initial infusion. Mice with NSCLC 
tumors treated with hiNSC-TRAIL therapy trended toward increased survival, likely limited by 
the tumor line’s partial TRAIL resistance. We also saw a significant increase in survival of mice 
with TNBC tumors treated with hiNSC-TRAIL, indicating the potential of this therapy in a 
TRAIL-sensitive tumor model.  
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While TRAIL is a useful cytotoxic protein for proof-of-concept studies and is well-
tolerated in humans,143 hiNSCs are not limited to using a monotherapy with TRAIL. Given the 
prevalence of tumor resistance to TRAIL,135,139,140,142,144–146 potential next steps include 
combining TRAIL with a drug/prodrug system. Our lab has previously shown that hiNSCs can 
be engineered to produce the prodrug-activator thymidine kinase, which has shown good results 
against glioblastoma in vivo.1,45 In this treatment paradigm, if a tumor shows resistance to 
TRAIL, a prodrug can be administered to initiate an additional therapy. Another option is to 
combine hiNSC-TRAILs with radiation therapy. Given the prevalence of radiation therapy to 
treat both NSCLC and TNBC,147–150 it will be key to study this interaction in the future. In this 
treatment paradigm, hiNSC-TRAIL would scavenge remaining tumor sites post-radiation. 
Furthermore, radiation can sensitize tumors to TRAIL142 and promote migration by increasing 
expression of hypoxic and inflammatory markers.120,151–153 
The therapeutic effect of hiNSC-TRAIL cells was limited in this model by the flow of cells 
through vessels. Our results indicate the intravenously infused hiNSCs immediately travel to the 
lungs and persist for at least two weeks. Our cell therapy takes advantage of this first pass 
through the lungs in the case of treating orthotopic lung tumors. We anticipate we would observe 
a stronger therapeutic effect in the case of TNBC if the cells were able to pass through the lungs 
more quickly. Previous studies have indicated that smaller cells, such as bone marrow-derived 
mononuclear cells (BMMC) with a cell volume of 150 μm3, are more likely to pass through the 
lungs into arterial circulation than larger cells, such as NSCs with a cell volume of about 2500 
μm3.154 Human T-cells, which have a volume the same order of magnitude as BMMCs,155 have 
been shown to distribute throughout the mouse following intravenous infusion in a similar 
fashion to a human.156 Thus, we anticipate the reason for the persistence of our human hiNSCs in 
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the lungs of mice is due at least in part to the large hiNSCs being unable to pass through small 
mouse lung capillaries.157,158 
Despite the lengthy persistence of hiNSCs in the lungs, they do not appear to cause 
significant toxicity. Following infusion of hiNSCs, there was no concerning inflammatory 
response observed in the lungs, liver, kidneys, or spleen. Only mild reactive changes were 
observed in the germinal centers of the spleen at early post-infusion time points that appear to 
decrease over time. Elevated creatinine levels returned to baseline 1 month after infusion. This 
correlates with our previous canine study in which induced neural stem cells transdifferentiated 
from canine fibroblasts showed no signs of significant iNSC-related tissue abnormality for 
greater than 84 days after injection.131 When compared to the significant toxicities associated 
with current chemotherapies such as taxol,159 the variations we observed from baseline in 
histology, hematology, and clinical chemistry values after infusion are comparably mild and 
transient.  
While we recognize the limitations of our current model, we still observed migration to 
both NSCLC and TNBC tumors following intravenous infusion of hiNSCs. To our knowledge, 
this is the first study to investigate the potential of any NSC to treat NSCLC following 
intravenous infusion. Furthermore, this is the first study to use hiNSCs to treat either NSCLC or 
TNBC. Mice with TNBC or NSCLC tumors showed significant reduction following intravenous 
hiNSC-TRAIL therapy. To further improve the therapeutic efficacy of these cells, we are 
currently in the process of developing a second generation of hiNSCs with more rapidly 
migrating cells and increased residence time. Moreover, future studies should also examine the 
impact of hiNSCs on patient-derived tumors. Overall, these are promising findings in the 
development of this cell therapy with implications to treat a variety of different cancers. 
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2.4 MATERIAL AND METHODS 
2.4.1 CELL LINES 
Cancer cell lines NSCLC A549, and NSCLC H460 and hTERT-immortalized human 
fibroblast line NHF1 were obtained from University of North Carolina Tissue Culture Facility. 
TNBC MDA-MB-231-Br cell line was obtained via MTA (Toshi Yoneda, PhD). All cell lines 
were cultured in Dulbecco’s modified eagle medium (DMEM; Gibco) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (Millipore), 100 Units/mL penicillin (Gibco) and 100 
g/mL streptomycin (Gibco), and 0.01% (v/v) PlasmocinTM (Invivogen). Cell lines were treated 
for mycoplasma with 0.05% (v/v) PlasmocureTM (Invivogen) for 2 weeks and were tested for 
mycoplasma with the MycoAlertTM mycoplasma detection kit (Lonza). 
 
2.4.2 HINSC GENERATION 
5 × 104 hTERT-immortalized NHF1s were seeded in 6-well plates and transduced with 
LV-GFP-TRAIL, LV-GFP-Nano Luciferase (NLuc),160 or LV-mC-Firefly Luciferase (FLuc) 
with 8 μg/mL polybrene (Thermo Fisher Scientific) for 12 hours in DMEM supplemented with 
10% FBS, 1% penicillin/streptomycin, and 0.01% PlasmocinTM. After initial transduction, cells 
were transduced with a cocktail of LV-SOX2 and LV-rtTA with polybrene for 12 hours in 
supplemented DMEM. A week prior to use of cells, 1 × 106 transduced cells were seeded per 
T175 flask in supplemented DMEM. Cells were cultured in STEMdiff Neural Induction Media 
(STEMCELL Technologies) with 2 μg/mL doxycycline (Sigma), changing media every other 
day for 5 days. Cells were detached using Accutase Cell Detachment Solution (STEMCELL 
Technologies) at room temperature and strained using 100 μm Falcon Cell Strainers (Fisher 
Scientific). SOX2 expression was verified by staining. Briefly, cells were fixed with 2.5% 
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formalin for 20 minutes and rinsed with PBS. Following incubation in blocking buffer for 1 hour 
at room temperature, cells were incubated with 1:100 rabbit anti-SOX2 antibody (Abcam) for 1 
day at 4C. After washing thrice with PBS, cells were incubated with 1:1000 goat anti-rabbit 
cross-adsorbed secondary antibody, Alexa Fluor 568 (Thermo Fisher Scientific) for at least 1 
hour. Cells were washed thrice with PBS and incubated in Hoechst for 20 min. Cells were 
imaged using an EVOS FL Auto Cell Imaging System (Life Technologies). 
 
2.4.3 IN VITRO THERAPEUTIC EFFECTS OF HINSC-TRAIL AGAINST CANCER 
CELL LINES 
5 × 103 cancer cells (MDA-MB231-Br or A549) labeled with stable expression of FLuc 
were seeded in 24-well plates in 10% FBS, 1% penicillin/streptomycin, and 0.01% PlasmocinTM 
DMEM. The following day, wells were seeded with varying numbers of hiNSC-TRAIL cells, 
from 0 to 10,000 cells/well. After 1, 3, and 7 days, viability of the cancer cells was assessed by 
adding 0.225 μg/mL luciferin and measuring luminescence using a SynergyH1 microplate reader 
(BioTek) at 1-sec per well measurement (N=4) or IVIS® Kinetic (Caliper Life Sciences) (N=4-
8). Viability was determined by dividing the luminescent signal of these wells to their untreated 
counterparts at each time point. To test viability of hiNSCs after exposure to recombinant human 
TRAIL (Sigma), we incubated hiNSCs expressing FLuc with 1-500 ng/mL TRAIL for 48 hours 
before assessing luminescence on SynergyH1 microplate reader as described above. 
 
2.4.4 IN VITRO HINSC MOTION AND MIGRATION 
24-well plates were prepared by incubating the empty wells with 32 ng/mL purified 
mouse laminin (EMD Millipore) in PBS for 12 hours at 37°C. Following incubation, media was 
aspirated and wells air-dried. Two-chamber cell culture inserts (Ibidi) were placed in each well. 1 
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× 104 hiNSC-mC-FLuc were seeded on the left side; 2 × 104 A549-GFP-NLuc (N = 6) or MDA-
MB231-Br-GFP-NLuc (N = 4) in 80 μL were seeded on the right side of inserts (0.5 mm 
separation). Both hiNSCs and tumor cells were cultured in STEMdiff Neural Induction Media 
(STEMCELL Technologies). 24-hours after seeding cells, inserts were removed, and wells were 
filled with STEMdiff Neural Induction with 2 μg/mL doxycycline (Sigma) and 2% FBS. Cells 
were imaged at 10x magnification every 2 hours for 96 hours with EVOS FL Auto Cell Imaging 
System (Life Technologies). 4 beacons per group were tracked. 10 random cells from each 
beacon were selected and individually tracked over time (ImageJ). Cell tracking data collected in 
Fiji was uploaded into R for statistical analysis and generating rose and summary violin plots. 
Number of cells migrated was determined by manually counting the cells that passed a starting 
line designated by the leading hiNSC edge at 0 hours. 
 
2.4.5 IN VIVO BIOLUMINESCENCE IMAGING 
To follow tumor volume or hiNSC-mC-FLuc distribution and persistence, serial 
bioluminescent imaging (BLI) was performed as previously described.1,45 Mice were 
administered D-luciferin (3 mg per mouse in 200 L of PBS) via intraperitoneal injection. 15 
min following injection, photon emission was measured using Ami HT (Spectral Instruments 
Imaging) or IVIS® Kinetic (Caliper Life Sciences). Luminescence was quantified through 
analysis with Aura (Spectral Instruments Imaging). 
 
2.4.6 TISSUE HARVEST AND PROCESSING 
Following anesthetization with 5% isoflurane, mice were perfused via intracardiac 
puncture with 10 mL PBS. Lungs were inflated with 10% neutral buffered formalin (NBF). 
 
43 
Lungs, liver, kidneys, and spleen were incubated in 10% NBF for 72 hours before storage in 
70% ethanol. Blood samples were analyzed by UNC Animal Histopathology Core. Organs were 
embedded in paraffin, sectioned, and stained with H&E by UNC Animal Histopathology Core 
and UNC Translational Pathology Laboratory.  
 
2.4.7 IN VIVO MIGRATION STUDIES 
For the lung tumor model, A549-GFP-NLuc cells were prepared by washing cells in 
suspension with PBS and preparing 1.5 × 106 cells in 50 μL 1:1 (v/v) Matrigel matrix (Corning) 
in PBS. Following anesthetization with isoflurane, athymic nude mice were placed in a lateral 
decubitus position. Cells were injected into intercostal space of left lung. Tumor growth was 
monitored using bioluminescent imaging by intravenous injection of furimazine (Promega; 1:20 
v/v in PBS). Tumors grew for two weeks. For the breast tumor model, MDA-MB231-Br-GFP-
NLuc were prepared as above and brought to a concentration of 2 million cells in 60 L 1:1 (v/v) 
Matrigel matrix (Corning) in PBS. Cells were injected into mammary fat pad. Tumors grew for 
10 days. 1 × 106 hiNSC-mC-FLuc cells suspended in 200 μL were intravenously injected. 
hiNSC-mC-FLuc was followed by BLI following intraperitoneal injection of luciferin. hiNSC-
mC-FLuc were also injected as described above in mice without tumors. Mice were sacrificed at 
3, 7, and 14 days after hiNSC-mC-FLuc injection (N=2 per time point). Lungs and fat pad 
tumors were processed as described above with the following exception: no perfusion was 
performed prior to removal of lungs to avoid disruption of cells for mice with lung tumors. 
Lungs and fat pad tumors were incubated in 10% NBF for 24 hours prior to storage in 30% 
sucrose at 4 C. Samples were frozen in optimal cutting temperature (OCT) media. Using a 
cryostat, 10 m organ sections were collected, stained with Hoechst (Thermo Scientific™), and 
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mounted with ProLongTM Gold Antifade Mountant (Invitrogen). Fluorescent images were 
collected using Olympus FV3000RS confocal microscope, and fluorescent signal was quantified 
using ImageJ. All images were optimized for brightness/color contrast. 
 
2.4.8 IN VIVO THERAPEUTIC EFFICACY STUDIES 
Lung H460-mC-FLuc (5 × 104 cells in 30 μL 2:1 Matrigel (v/v) in PBS) or breast MDA-
MB231-Br-mC-FLuc were implanted as described above in athymic nude mice. Tumor volumes 
were monitored using BLI. Maximum tolerated dose of 1 × 106 hiNSC-TRAIL cells suspended 
in 200 μL PBS were injected intravenously 4 and 8 days after H460 tumors implantation or 5 
days after MDA-MB231-Br implantation. The orthotopic H460 tumor study was completed 
twice in order to increase N, and multiple unpaired t-tests were used to determine no significant 
difference between controls and hiNSC-TRAIL groups of the first and second studies. Mice 
without visible thoracic tumors with a 2-second exposure via BLI by Day 14 were excluded. BLI 
values for individual days were excluded if a value dropped by an order of magnitude from 
previous time point and then increased by an order of magnitude by the next time point, 
presumably because of a poor intraperitoneal injection of luciferin. N = 15 was used for controls, 
and N = 16 was used for treatment mice with H460 tumors. N = 5 for treated mice and 4 for 
control mice with MDA-MB231-Br tumors. Grubbs’ test was used to identify outliers, and these 
mice were excluded. Mice were sacrificed when they lost >20% of their highest body weight, 
exhibited signs of distress, or if a visible tumor exceeded 2 cm in width. Survival is reported as 




2.4.9 IN VIVO TOXICITY STUDIES 
In order to test the toxicity of either carrier hiNSC-mC-FLuc or cytotoxic hiNSC-TRAIL, 
1 × 106 hiNSC-mC-FLuc or 1 × 106 hiNSC-TRAIL cells in 200 μL PBS were injected 
intravenously into athymic nude mice (N = 4 per time point). 3, 7, 14, and 28 days following 
injection, 700 μL of blood was collected via intercostal puncture, and organs were harvested 
following perfusion with PBS. Blood was collected in K2 EDTA Microtainer™ (BD) and in clot 
activator Microtainer™ (BD), from which serum was extracted. Blood and serum samples were 
analyzed by the UNC Animal Histopathology Core. 
 
2.4.10 ETHICS STATEMENT 
All experimental mouse protocols were previously approved by the Institutional Animal 
Care and Use Committees at University of North Carolina -- Chapel Hill. 
 
2.4.11 STATISTICS 
Data were analyzed using GraphPad Prism and R. Multiple unpaired t-tests without 
correction for multiple comparisons were used to compare two groups. Multiple groups were 
analyzed by one-way ANOVA, followed by Dunnett’s post-hoc test. Survival analysis was 
conducted using a Log-rank test. Unless otherwise specified, all values are expressed as mean +/- 









CHAPTER 3: DEVELOPMENT OF NEXT-GENERATION TUMOR-HOMING 
INDUCED NEURAL STEM CELLS TO ENHANCE TREATMENT OF METASTATIC 
CANCERS2 
3.1 INTRODUCTION 
Despite advances in clinical care, metastatic brain cancer remains a major medical 
challenge. Breast cancer is the second most common cancer to metastasize to the brain 35. 
Among breast cancers, triple-negative breast cancer (TNBC) has the highest incidence of central 
nervous system (CNS) metastasis, affecting nearly 30% of patients 161. However, the options to 
treat TNBC brain metastasis are limited due to the lack of targetable surface markers on these 
tumor cells. Radiation treatment, surgical resection, or chemotherapy remain the standard of care 
42,162, but the median survival after diagnosis of CNS disease is less than 5 months 40,162,163. CNS 
metastases can be further subcategorized to parenchymal metastases (PM) or leptomeningeal 
carcinomatosis (LC) depending on the site of tumor infiltration 164. Although the incidence rate 
of LC in all patients with breast cancer is only about 5% 165, the median overall survival for 
patients with breast cancer LC is as little as 4 weeks 164. Treatment typically consists of a 
multimodal approach that includes systemic or intrathecal chemotherapy and radiation, but there 
is no generally accepted standard of care currently available for the treatment of breast cancer 
LC 166. Effective therapies are urgently needed to improve outcomes for patients with TNBC 
CNS disease and, particularly, LC.  
 
2 Chapter was adapted from an article published at Science Advances. The original citation is as follows: W. Jiang, 
Y. Yang, A. R. Mercer-Smith, A. Valdivia, J. R. Bago, A. S. Woodell, A. A. Buckley, M. H. Marand, L. Qian, C. K. 
Anders, S. D. Hingtgen, Development of next-generation tumor-homing induced neural stem cells to enhance 




During the past 20 years, engineered neural stem cell (NSC)-mediated therapies have 
emerged as a promising therapeutic strategy against brain tumors in preclinical and clinical 
studies 44,134,167,168. Leveraging their innate tumor tropism, engineered NSCs have been shown to 
migrate through the brain, homing to tumor foci and delivering therapeutic payloads to induce 
effective tumor killing. Recently, the emergence of advanced cell reprogramming technology has 
led to the generation of induced NSCs (iNSCs). Generated by transdifferentiating somatic 
fibroblasts directly into NSCs without the need for a pluripotent stage 45,96,97, the ease of 
isolation, and the ability to provide an autologous therapy to avoid immune rejection suggests 
that iNSC technology may offer advantages over other cell carriers. We previously provided the 
first results that showed the potential of iNSCs as tumor-homing drug carriers capable of 
regressing glioblastoma (GBM) xenografts 169. Using a defined set of transcription factors, we 
previously reprogrammed human and mouse fibroblasts into iNSCs that homed to GBM cells 
with a similar velocity as brain-derived NSCs and migrated through the brain, tracking invasive 
human brain cancer cells 1,129. Genetically engineered iNSCs released the pro-apoptotic agent 
tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL) (hiNSCsTR) at levels equal to 
cortical-derived NSCs and killed co-cultured brain cancer cells 129. In orthotopic xenograft 
models, hiNSCsTR therapy reduced solid human brain cancer foci, suppressed post-surgical brain 
cancer, and more than doubled median survival of tumor-bearing mice 1.  
Here, we report the development of a second-generation iNSC delivery platform. We 
provide the first evidence that a neurosphere-based culture system creates human induced 
neurosphere (hiNeuroS) with a unique genetic profile and significantly enhanced anti-tumor 
capabilities. Single-cell genomic profiling revealed that hiNeuroSs were enriched for a unique 
set of tumor-homing gene pathways, and in vitro kinetic migration studies showed that 
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hiNeuroSs rapidly migrate to tumor cells faster than first-generation iNSC (hiNSC). Using 
intracerebroventricular (ICV) delivery as a clinically-compatible infusion route and mouse 
models of human TNBC PM, we found that hiNeuroSs populate solid metastatic brain foci at 
more than twice the level of hiNSC while persisting for over 45 days, nearly fourfold longer than 
first-generation cells. Real-time kinetic tracking showed that the hiNeuroS delivery of TRAIL 
reduced TNBC PM over fourfold, significantly extended median survival, and allowed 33% of 
animals to survive long term, while control and hiNSC-treated mice died within 30 days. Using a 
mouse model of human LC disease, prophylactic hiNeuroS therapy markedly delayed the 
development of TNBC LC with 50% of mice surviving over 80 days after treatment. hiNeuroS 
therapy also reduced the progression of established LC foci while doubling the survival of 
tumor-bearing animals. Together, we provide the first evidence that a novel hiNeuroS therapy 
may be a highly effective strategy for the treatment of metastatic brain cancer.  
 
3.2 RESULTS 
3.2.1 HINEUROS GENERATION AND CHARACTERIZATION 
The tumor-homing properties of iNSCs are the most unique and beneficial aspect of this 
therapy. We previously found that growing cells in clusters improves migratory capabilities 84. 
This suggested that a second-generation iNSC with improved functionality could be created by 
cluster-based culture.  To create a second-generation tumor-homing iNSC, we adapted our 





Figure 3.1. hiNeuroS generation and characterization. (A) Schematic of hiNeuroS generation process with SOX2 
single factor cell reprogramming system. (B) Bright field (BF) and mCherry fluorescence images of hiNeuroS-mC-
FLuc spheres generation process. Scale bar = 200 μm. (C) BF and GFP fluorescent images of hiNeuroS-TRAIL 
sphere generation process. Scale bar = 200 μm. (D) Fluorescent images showing both hiNeuroS-mC-FLuc spheres 
and hiNeuroS-TRAIL spheres stained for SOX2. Scale bars = 100 μm. (E) Fluorescent images showing both 
hiNeuroS-mC-FLuc spheres and hiNeuroS-TRAIL spheres stained for Nestin. Scale bar = 100 μm. 
through multiple rounds of sphere formation and dissociation (Fig. 3.1A). Human fibroblasts 
(NHF-1) were transduced with lentivirus encoding SOX2 under the tetracycline-inducible 
promoter rtTA. Co-transduction with lentiviral vectors encoding optical reporters (mCherry-
firefly luciferase; LV-mC-FLuc) or the cytotoxic agent TRAIL (LV-TRAIL-green fluorescent 
protein (GFP)) were then used to create diagnostic or therapeutic variants. Reprogramming and 
sphere formation were simultaneously initiated by transferring the cells to laminin-coated flasks 
and culturing in ReNCell NSC growth media.  Two weeks after transduction, we detected 
clusters of cells that continued to increase in size and number through a month of culturing (Fig. 
3.1, B and C). Unexpectedly, imaging showed that the TRAIL spheres required more time to 
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reach the same size and number as the diagnostic cells. However, the expression of SOX2 and 
the NSC marker Nestin was detected in both sphere variants (Fig. 3.1, D and E), suggesting the 
successful generation of NSC-like cells which we termed hiNeuroS. 
Previously, we and others have shown that a continuum of genetic changes occurs as 
fibroblasts are converted into iNSCs through the transdifferentiation (TD) process 96,97,99,169. To 
understand the transcriptomic profile of cells during our sphere-based generation of hiNeuroS, 
we performed single-cell RNA sequencing (scRNA-seq) and real-time polymerase chain reaction 
(PCR) analysis. By ordering cells from different samples along a developmental trajectory, we 
found that while some of the hiNeuroS cells shared a similar trajectory state with the fibroblasts, 
there was a unique cell group at the far end of hiNeuroS trajectory toward the latest pseudotime 
circled in red (Fig. 3.2, A and B). Pseudotemporal gene expression analysis clustered genes with 
similar gene expression pattern over pseudotime and showed that the genes in cluster 1 had 
relatively high expression levels for the most of the “time” but gradually downregulated toward 
the end, while the genes in cluster 2 had the opposite expression pattern (Fig. 3.2C). Functional 
annotations revealed that cluster 1 actually contained more fibroblast-related genes, while cluster 
2 contained more NSC-related genes, verifying the cell type transition from fibroblast to 
hiNeuroS within the cell reprogramming process. This conclusion was also confirmed by the 
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment 
analysis of the two clusters, which showed that genes in cluster 1 were enriched for the GO terms 
related to fibroblasts, whereas those in cluster 2 were enriched for the terms related to NSCs 





Figure 3.2. hiNeuroS cell reprogramming dynamics. (A) Single-cell trajectory analysis revealing the formation of 
a unique cell group towards the far end of trajectory (circled in red). (B) Bar graph showing the proportion of 
different cell subgroups within hiNeuroS or fibroblast samples at different pseudotime periods. (C) Pseudotemporal 
gene expression analysis revealing the trend of downregulation of fibroblast- related genes and upregulation of 
NSC-related genes along the trajectory. (D) GO and KEGG enrichment analyses showing that the unique cell group 
at the end of the trajectory possessed more NSC-related functions and less fibroblast-related functions. 
We next explored transcriptional differences between hiNeuroS and the parental 
fibroblast at individual gene level to reveal the expression differences among several key  
signaling pathways not only related to NSC property, but also mediating cell tumor-homing 
migration. We also compared the gene expression of these key biologic parameters between 
hiNeuroS and hiNSC to uncover differences and improvements between the original hiNSC 
carrier and our new sphere-based carriers. Although the expression of many genes was conserved 
between fibroblasts and hiNeuroS, clear and distinct transcriptional changes were present in 
hiNeuroS. hiNeuroS also showed transcriptional changes that were distinct from the older first-
generation hiNSC, suggesting that the new neurosphere-based culture system has created 
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Figure 3.3. Differential transcriptomic profile of fibroblasts, hiNSC, and hiNeuroS. (A) Principal 
components analysis (PCA) of three cell types visualized on PCA plot. Different cell types are 
represented by different colors. (B) Heatmap of euclidean distance of pseudo-bulk transcriptome between 
three cell types.  (C) Dot plot showing expression of canonical NSC markers for each cell type. (D) Heat 
map revealing stem cell migration-, stemness-, and proliferation-related genes specifically upregulated in 
hiNeuroS. (E) Bar graphs of relative gene expression level showing NSC tumor tropism related cell 
surface receptor genes were significantly upregulated in hiNeuroS in comparison with hiNSC or 
fibroblasts. ** p-value < 0.01; *** p-value < 0.001. n = 3 technical replicates for qPCR analysis. 
different cell product (Fig. 3.3, A and B, and Appendix B.1). We also found that hiNSCs and 
hiNeuroSs all expressed classic markers of brain-derived NSCs, yet the expression patterns 
differed substantially between hiNSC and hiNeuroS (Fig. 3.3C). Tumor-homing migration is one 
of the most unique and critical aspects of NSC/iNSC cell therapy. When we focused our analysis 
on cell migration, as well as stemness and proliferation pathways, we found a list of genes 
associated with these pathways that were activated in hiNeuroS at high levels, but these same 
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genes showed little or no activation in parent fibroblasts or hiNSC (Fig. 3.3D). Tumor-homing 
migration is mediated by the binding of soluble factors released from the tumor to surface 
receptors on NSC/iNSCs. When we analyzed the expression of cell surface receptor genes 
involved in NSC tumor tropism 45,133,167,168,170, we found that the CXCR4, FLT1, IL6R, MET, 
and PLAUR were all expressed in hiNeuroS at levels 1.8- to 20-fold higher than in hiNSC or 
fibroblasts. (Fig. 3.3E). These data suggest that our new neurosphere-based culture method 
generated hiNeuroS cells that are a genetically distinct NSC sub-population that expresses 
tumor-homing pathways-associated genes at levels significantly greater than hiNSC.  
Together, these results suggest that our new sphere-based TD method has generated a 
distinct, second generation of iNSC. In comparison with the first generation (hiNSC), hiNeuroSs 
have a unique NSC-related gene expression profile with markedly enhanced expression of genes 
related to NSC tumor tropism. As this suggests that hiNeuroSs may represent a more effective 
anti-cancer therapy, we next investigated the homing and efficacy of this new cell both in vitro 
and in vivo. 
 
3.2.2 ASSESSING HINEUROS MIGRATION CAPABILITY TOWARD TNBC BRAIN 
METASTASIS IN VITRO 
To investigate whether the improved gene expression profile of hiNeuroS translated into 
enhanced tumor tropism, we performed in vitro two-dimensional co-culture cell migration assays 
using real-time imaging to monitor cell motion over 72 hours (Fig. 3.4A). The fluorescent 
images showed that compared to controls, hiNeuroS directionally migrated towards tumor cells 
within 72 hours (Fig. 3.4B), but not toward normal fibroblasts (Appendix B.2). When compared 
to hiNSCs, greater numbers of hiNeuroS crossed the starting line at both 48 and 72 hours, with 
more than twice as many hiNeuroS migrating to tumors at the later time point (Fig. 3.4C). We 




Figure 3.4. hiNeuroS and hiNSC in vitro migration towards MB231-Br. (A) Schematic of in vitro migration 
assay. (B) Fluorescent images showing hiNeuroS and hiNSC movement when in the presence or absence (control) 
of tumor cells. The white dotted lines indicate the position of hiNeuroS or hiNSC at time 0; the red dotted lines 
indicate the position of hiNeuroS or hiNSC at time 72 hours. Scale bar = 100 μm. n.s., not significant.  (C) Bar 
graph of number of migrated cells, defined as the number of cells that crossed the white dotted line at time 0, in the 
presence or absence (control) of tumor cells over time. (D) Box and whisker plots for directionality, (E) final 
displacement, and (F) velocity for hiNeuroS and hiNSCs in the presence and absence (control) of tumor cells. a.u., 
arbitrary unit. The box represents 75th percentile, median, and 25th percentile; the whisker represents maximum and 
minimum values.  (G) Single cell tracing plots for hiNeuroS and hiNSC.  Red lines indicate “Fast Migrating” cells 
with a final displacement more than 250 μm; cells with a final displacement less than 250 μm were defined as “Slow 
Migrating” cells and were marked in blue. (H) Bar graph percentage of Fast and Slow Migrating cells in the 
hiNeuroS and hiNSC groups. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. n = 4 technical replicates.  
hiNeuroS. Compared to hiNSC, hiNeuroS migrated nearly 1.5 times as fast with more than 1.2 
times the directional motion, allowing the cells to cover nearly two times the displacement of 
hiNSC (Fig. 3.4, D to F). In addition, we investigated how both hiNSCs and hiNeuroS could 
have sub-populations of particularly fast migratory cells. We defined “fast migrating cells” as  
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those that had a final displacement of 250 m. Single-cell motion analysis and quantification 
revealed that 87% of hiNeuroS were “fast migrating cells”, compared to only 40% of hiNSCs 
(Fig. 3.4, G and H). Together, these data suggest that hiNeuroS not only are tumoritropic but 
also demonstrate enhanced tumor tropism in vitro compared to hiNSCs.  
 
3.2.3 INVESTIGATING THE IN VIVO KINETICS OF HINEUROS THERAPY 
FOLLOWING ICV INFUSION 
In the clinical setting, ICV infusion is used to deliver chemotherapeutic agents across the 
blood-brain barrier (BBB) and to facilitate whole-brain delivery. To leverage the advantage of 
ICV route of administration, we chose to administer our cell therapy via ICV infusion to explore 
the homing and efficacy of hiNeuroS therapy for TNBC brain metastasis. To investigate the 
tumor homing and persistence of hiNeuroS therapy following ICV infusion in vivo, hiNeuroS-
mC-FLuc cells were ICV-infused 1 week after TNBC tumor implantation in the brain 
parenchyma of mice (Fig. 3.5A). The fluorescent images of post-mortem brain sections revealed 
that hiNeuroSs extravasated from the ventricular system and migrated to the tumor site in as little 
as 3 days after ICV infusion, where the cells persisted for at least 2 weeks (Fig. 3.5C). Although 
a similar cell tumor-homing pattern was observed for hiNSC after ICV infusion (Fig. 3.5B and 
Appendix B.3), the hiNSC/hiNeuroS-to-tumor ratio for fluorescence intensity showed that 
twofold more hiNeuroS reached the tumor foci than hiNSC at all days 3, 7, and 14 (Fig. 3.5D). 
We next investigated the persistence of hiNeuro using the same in vivo models. Serial 
bioluminescence imaging (BLI) showed that first-generation hiNSCs were rapidly cleared with 
the hiNSC signal dropping below detection within 11 days after infusion (Fig. 3.5, E and F). 
hiNeuroS showed a markedly different pattern of persistence. The quantification of the BLI 
suggested that the average hiNeuroS level (2.6  107) was significantly greater than hiNSCs (1.3 
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 105) at 2 weeks after infusion. In particular, the hiNeuroS signal increased significantly 4 days 
after infusion and then declined gradually with cells remaining visible through 45 days after 
transplant by BLI in a subset of mice (Appendix B.4). Together, these results suggest that 
hiNeuroSs exhibit enhanced tumor homing and extended persistence compared to first-
generation cell carriers. As these beneficial properties may allow hiNeuroS to achieve robust 
therapeutic effects, we next explored the efficacy of hiNeuroS therapy in different models of 
aggressive metastatic brain cancer.  
Figure 3.5. hiNeuroS and hiNSC in vivo migration and persistence following ICV infusion. (A) Schematic of in 
vivo migration assay toward MB231-Br brain parenchymal tumor. (B) Fluorescent images of brain cross-sections 
showing the presence of hiNSC (red) at tumor foci at different time points after ICV infusion. mCherry channel 
presented only. Scale bar = 100 μm (C) Fluorescent images of brain cross-sections showing the presence of 
hiNeuroS (red) at tumor foci (green) at different time points after ICV infusion. Scale bar = 100 μm (D) Bar graph 
showing hiNeuroS-mC or hiNSC-mC to MB231-Br-GFP ratio for fluorescence intensity at different time points 
after ICV infusion. n = 6 technical replicates. (E) Representative BLI images showing in vivo persistence of 
hiNeuroS and hiNSC following ICV infusion. (F) Bar graph of ICV-infused hiNeuroS or hiNSC BLI signal in vivo 




3.2.4 EXPLORING THE EFFICACY OF HINEUROS-BASED THERAPY IN 
TREATING TNBC BRAIN PM BY ICV INFUSION 
After showing that hiNeuroS was able to rapidly populate the tumor foci following ICV 
infusion with long term persistence, we next assessed the therapeutic effect of ICV-infused 
hiNeuroS therapy. We began by testing hiNeuroS therapy in vitro using hiNeuroS-TRAIL cells. 
mCherry+ TNBC brain metastasis tumor cells were co-cultured with hiNeuroS-TRAIL cells at 
increasing ratios, and real-time fluorescence images were collected every 24 hours for 3 days. 
We found that hiNeuroS-TRAIL cells reduced the MDA-MB231-Br signal in a dose-dependent 
manner with the highest ratio of hiNeuroS-TRAIL to MB231-Br ratio (2:1) reducing the MDA-
MB231-Br signal by 50% within 24 hours while the lowest ratio of 1:10 showed >75% reduction 
in tumor cells compared to control after 72 hours (Fig. 3,6, A and B, and Appendix B.5).  
To explore the efficacy of hiNeuroS-TRAIL therapy in vivo, we stereotactically 
implanted MDA-MB231-Br-mC-FLuc cells into the brain parenchyma of mice. Three days after 
tumor implantation, hiNeuroS-TRAIL, saline control, or first-generation hiNSC-TRAIL cells 
were infused in the contralateral ventricle. Serial tumor BLI showed that a single dose of 
hiNeuroS-TRAIL delivered ICV reduced tumor volumes fourfold at day 27 after infusion and 
increased median survival over control mice from 38 to 52 days (HR: 0.23 95% CI 0.05-0.98) 
(Fig. 3.6, C, D, and F). Importantly, 33% of the mice treated with hiNeuroS-TRAIL therapy 
were still alive at the end of the study (Appendix B.6). In contrast, no significant tumor 
suppression or survival extension was observed following ICV-infused hiNSC-TRAIL therapy, 
suggesting that the improved genomics and persistence of hiNeuroS led to enhanced tumor kill 
(Fig. 3.6, E and G). Together, these data suggest that ICV hiNeuroS can have a significant 




Figure 3.6. ICV-infused hiNeuroS- and hiNSC-TRAIL therapy against TNBC brain PM. (A) Fluorescent 
images of MB231-Br cells treated with various ratios of hiNeuroS-TRAIL cells over time. Scale bar = 100 μm (B) 
Bar graph of MB231-Br cell fluorescence intensity fold change over time (standardized to untreated MB231-Br) 
after treated with various ratios of hiNeuroS-TRAIL cells. n = 8 technical replicates. (C) Representative MB231-Br 
brain parenchymal tumor BLI images following ICV infusion of hiNeuroS-TRAIL. (D) Tumor volume fold change 
standardized to day 1 following ICV infusion of hiNeuroS-TRAIL or PBS (control). n = 6 for both hiNeuroS-
TRAIL and control groups. (E) Tumor volume fold change standardized to day 1 following ICV infusion of hiNSC-
TRAIL or PBS (control). n = 4 for both hiNSC-TRAIL and control groups. (F) Kaplan-Meier survival curve for 
mice with a MB231-Br brain parenchymal tumor treated with ICV PBS (control) or hiNeuroS-TRAIL. (G) Kaplan-
Meier survival curve for mice with a MB231-Br brain parenchymal tumor treated with ICV PBS (control) or hiNSC-
TRAIL. * p-value < 0.05; *** p-value < 0.001. 
3.2.5 EVALUATING ICV-INFUSED HINEUROS-BASED THERAPY IN TNBC LC 
LC is one of the most lethal forms of breast-to-brain metastases, with patients with LC 
surviving as little as 4 weeks after diagnosis 164. In LC, metastatic tumor cells spread through the 
leptomeningeal space surrounding the brain and the spinal cord, forming multi-focal tumors. 
There is an urgent need for treatments that improve targeting the tumors established in the 
leptomeninges or floating tumor cells before they can engraft. On the basis of the promising 
results of hiNeuroS-TRAIL therapy in models of TNBC brain PM, we next sought to assess the 
potential of ICV-delivered hiNeuroS-TRAIL therapy to treat TNBC LC. To mimic the spread of 
cancer cells within cerebrospinal fluid and subsequent seeding throughout the leptomeningeal 
space, MDA-MB231-Br-mC-FLuc cells were stereotactically infused into the cisterna magna of 
mice. To investigate hiNeuroS treatment of established LC tumors, we delivered hiNeuroS-
TRAIL cells or saline control via ICV infusion 3 days after tumor infusion to allow tumor foci to 
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form (Fig. 3.7A). In control-treated mice, serial BLI showed that the intracisternal injection 
generated tumors within the brain and spinal cord, which quickly expanded more than 122- and 
61-fold in the brain and spinal cord, respectively, in 17 days (Fig. 3.7, B, E, and H).  The 
fluorescence microscopy of post-mortem tissue sections 14 days after tumor injection confirmed 
that tumors spread throughout multiple regions of the brain (Fig. 3.7C) and across all three 
regions of the spinal cord of control-treated animals (Fig. 3.7D). Animals succumbed to the 
aggressive and diffuse tumors 25 days after infusion (Fig. 3.7I). In contrast, serial imaging and 
post-mortem tissue sections showed that ICV infusion of hiNeuroS-TRAIL cells markedly 
attenuated tumor progression (Fig. 3.7, B to D). Despite the diffuse and aggressive nature of the 
tumors, ICV infusion of hiNeuroS-TRAIL cells reduced the established tumor volumes 30-fold 
at 7 days after treatment (10 days after tumor implant) in the brain and reduced tumor in the 
spine below detection through 17 days after implant (Fig. 3.7, E to H, and Appendix B.7). ICV-
delivered hiNeuroS-TRAIL therapy doubled survival with hiNeuroS-TRAIL treated animals 
surviving a mean of 47 days (Fig. 3.7I).  
To model prophylactic hiNeuroS-TRAIL therapy for LC, therapeutic hiNeuroS-TRAIL 
cells were ICV-delivered first followed by intracisternal infusion of MDA-MB231-Br-mC-FLuc 
cells into the cisterna magna 7 days later. Serial imaging and post-mortem tissue sections showed 
that prophylactic ICV hiNeuroS-TRAIL cells significantly delayed tumor formation in both brain 
and spine (Fig. 3.7, B to H) and extended median survival to nearly 70 days (Fig. 3.7I). Within 
this treatment group, 33% of the animals showed no detectable signs of tumor growth in either 
brain or spine through 70 days after treatment (Appendix B.8), and 50% of the animals remained 
alive 3 months after infusion (Fig. 3.7I). Together, these data demonstrate the potential of ICV 
infusion of hiNeuroS-TRAIL therapy in treating or preventing TNBC LC.  
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Figure 3.7. ICV-infused hiNeuroS-TRAIL therapy against TNBC LC. (A) Schematic of study design for 
both prophylactic and established tumor treatment. In the prophylactic treatment study, hiNeuroS-TRAIL 
cells were infused ICV 7 days before tumor inoculation; In the established tumor study, hiNeuroS-TRAIL 
cells were infused ICV 3 days after tumor inoculation. (B) Representative MB231-Br tumor BLI images 
in the control (treated with PBS), prophylactic treatment, and established tumor treatment groups. (C) 
Fluorescent images of brain sagittal-sections 14 days after tumor (red) intracisternal injection for control, 
prophylactic treatment, and established tumor treatment groups. Hoechst stain shown in teal.  (D) 
Fluorescent and bright field images of cervical, thoracic, and lumbar spine longitudinal-sections 14 days 
after tumor (red) intracisternal injection in control, prophylactic treatment, and established tumor 
treatment groups. Hoechst stain shown in blue. Scale bar = 100 μm. (E and F) MB231-Br tumor BLI 
signal in the brain after PBS (control, blue), prophylactic treatment (red), or established tumor treatment 
(green) showing (E) as raw BLI signal and (F) as BLI signal standardized to day 1. (G and H) MB231-Br 
tumor BLI in the spine after PBS (control, blue), prophylactic treatment (red), or established tumor 
treatment (green) showing as (G) raw spine tumor BLI or (H) spine tumor BLI standardized to day 1. (I) 
Kaplan-Meier survival curve for control, prophylactic treatment, and established tumor treatment groups. 
n = 5 for control group; n = 6 for both prophylactic and established tumor treatment groups.  * p-value < 
0.05; ** p-value < 0.01; *** p-value < 0.001. 
3.3 DISCUSSION 
In this study, we successfully developed hiNeuroS, a second generation of iNSC therapy 
created by direct TD of human fibroblasts using a SOX2 single-factor cell reprogramming 
system. In comparison with the first-generation hiNSC, hiNeuroS demonstrated a distinct genetic 
profile, enhanced tumor tropism, and significantly improved in vivo persistence. In therapeutic 
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models, ICV-infused hiNeuroS therapy significantly attenuated the progression of both solid PM 
and LC metastatic disease.  
In the past two decades, numerous studies have proved the effectiveness of using NSCs 
as drug delivery system to combat primary and secondary brain tumors 44,118,123,129,136,169,171–173. 
While endogenous “off-the-shelf” NSCs and NSCs created by cellular reprogramming are the 
two major cell sources, the latter has therapeutic advantages because it opens up the possibility 
for personalized iNSCs transdifferentiated from a patient’s own cells, allowing for potentially 
reduced immunogenicity and increased persistence 45,170. Currently, the most commonly used 
methods to generate iNSCs from somatic fibroblasts involve either indirect cell reprogramming 
with the employment of classic Yamanaka reprogramming factors (OCT4, SOX2, KLF4 and c-
MYC) or direct TD by introducing lineage-specific transcription factors 97. Compared to indirect 
cell reprogramming, direct TD has a significantly reduced risk of teratoma formation during the 
cell generation process in vitro or after cell administration in vivo by circumventing the induced 
pluripotent stem cell (iPSC) stage; this makes direct TD-derived iNSC cell therapy a safer 
variant 96. We have generated both the first- and second-generations of transdifferentiation-
derived iNSCs, hiNSC, and hiNeuroS, through the direct TD process by using SOX2 as the sole 
cell reprogramming factor. While our data show that both hiNSC and hiNeuroS are positive for 
typical NSC markers (SOX2 and Nestin) 1, hiNeuroSs have a substantially enhanced 
transcriptomic profile in terms of migration and stemness and have demonstrated better 
functional performance. The differential gene expression profile of hiNeuroSs, especially the 
genes related to stemness, compared to hiNSCs could attribute to a few reasons. First, the 
spheroid culture system used to generate hiNeuroSs may play a critical role in the promotion and 
maintenance of cell stemness in hiNeuroSs. Several studies have shown the advantages of 
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spheroid stem cell culture system in comparison with monolayer stem cell culture system in 
terms of promoting the expression of genes related to not only stemness but also cell migration 
and proliferation174,175. Second, the long-term cell selection cycles during the hiNeuroS 
generation process may have potentially imposed selective pressure on the cell population, which 
contributed to the enrichment of the cells with high stemness. In addition, the different culture 
media used to generate hiNeuroS and hiNSC (ReNcell media vs. Neural Induction Media) may 
also drive the differential gene expression in stemness.  
The enhanced tumor tropism of hiNeuroS suggests its potential as a NSC-mediated drug 
delivery vehicle. Although the exact underlying mechanisms involved in NSC chemotaxis 
toward brain tumors are still being investigated, many studies have indicated that SDF-
1/CXCR4, uPA/uPAR (PLAUR), VEGF/VEGFR1 (FLT1), HGF/c-Met, SCF/c-Kit, and MCP-
1/CCL2 are major signaling pathways involved in NSC tumor tropism, especially towards 
gliomas 44,45,167,168. Zhao et al. also identified IL-6 as the major cytokine mediating NSC 
migration toward metastatic breast cancer 133. Here, we have shown that in comparison with 
human fibroblasts or hiNSCs, hiNeuroSs have significantly higher gene expression for the 
migratory receptors CXCR4, PLAUR, FLT1, c-MET, and IL6R, which likely contribute to the 
remarkable improvement in hiNeuroS in vitro migration in terms of tumor directionality, final 
displacement, and velocity, as well as enhanced in vivo tumor homing following ICV infusion. 
ICV-infused hiNeuroS cells migrated to tumor foci in as little as 3 days following administration. 
In addition to these key tumor tropism-related genes, we have also observed the upregulation of 
several other NSC migratory genes specifically in hiNeuroS but not hiNSCs, including RHOC 
176, CD44 177,178, and MMP3 179. The upregulation of these genes also likely contributes to the 
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enhanced tumor tropism observed in hiNeuroS. We are continuing to explore the precise 
contribution of each pathway to the tumor homing process in ongoing studies. 
Another key factor in the success of iNSCs is the in vivo persistence of this drug delivery 
vehicle as increased persistence can significantly extend the time of cytotoxic payload 
production and release, thereby improving therapeutic efficacy 171,180,181. As potential 
personalized therapies, hiNeuroS and hiNSC would reduce the need for immunosuppressive 
drugs which are typically used for allogeneic transplants to extend the persistence of the cells in 
a patient 182. In our mouse models, we showed that while a single dose of hiNSCs could persist in 
the brain for around 2 weeks after ICV infusion, a single ICV infusion of hiNeuroS cells was 
detectable for more than 45 days. The BLI signal of hiNeuroS increases for a week following 
cell administration, suggesting that the hiNeuroS cells were able to proliferate for a few days in 
vivo. This phenomenon may be the result of cerebrospinal fluid (CSF)-induced proliferation of 
NSC 183. NSC proliferation-related genes that were upregulated specifically in hiNeuroS 
population, such as MYC 184, may also contribute to this short-term cell proliferation after ICV 
infusion. Our in vitro study has shown greater hiNeuroS cell proliferation compared to hiNSC 
(Appendix B.9), but we are further characterizing the proliferative state of hiNeuroS at long-
term time points in vivo. We are also studying different cyto-ablation “switches” to ablate cells, a 
potentially important safe mechanism as hiNeuroS being moving toward first in human trials.  
ICV infusion was chosen as the preferred route of administration because it is a clinically 
established and extensively used CNS drug administration route with advantages including BBB 
circumvention and whole-brain coverage 185,186. While ICV infusion has been primarily 
employed to deliver chemotherapy to CNS tumors, its potential application for cell therapy 
delivery remains relatively unexplored 122,187,188. ICV-infused CAR-T cell therapies for GBM and 
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atypical teratoid/rhabdoid tumors (ATRTs) treatment are the only studies we have found so far 
using ICV as the cell therapy administration route to treat brain cancers 189,190. Other studies have 
demonstrated the migratory but not therapeutic potential of ICV infused stem cells for brain 
cancer treatment 122,188,191. To the best of our knowledge, we are not only the first to report the 
tumor homing of iNSCs towards TNBC brain PM tumor foci following ICV infusion but also the 
first to demonstrate a significant anti-tumor effect from ICV-infused iNSC therapy. In treating 
TNBC patients with brain metastasis, the current standard of care is limited to systemic 
chemotherapy, radiotherapy, and surgical resection, and no effective targeted therapy exists 40,192. 
In this study, however, we have made TNBC brain PM “targetable” with our newly developed 
second-generation iNSC therapy. By following the chemoattractants secreted by tumors and their 
microenvironment 44, ICV-infused hiNeuroS cells were able to rapidly populate the TNBC brain 
PM tumor foci. To test the therapeutic efficacy of hiNeuroS-mediated therapy, we genetically 
engineered our drug delivery vehicle to secret TRAIL as TRAIL is generally not harmful to 
healthy cells 193–198. With a single dose of ICV-infused hiNeuroS-TRAIL cells, we found that we 
were able to significantly suppress tumor growth in the brain parenchyma and extend the median 
survival by 37%. Although hiNSC cells were also observed around the tumor foci following ICV 
infusion, no significant therapeutic effect was observed, likely due to the smaller number of 
hiNSCs that homed to the TNBC brain tumor and their shorter persistence in vivo.  
After we determined the therapeutic potential of hiNeuroS-TRAIL to treat TNBC 
parenchymal brain tumors, we explored their use in the treatment of TNBC LC, a late-stage 
metastatic complication of TNBC where tumor cells invade the leptomeningeal space 
surrounding the brain and spinal cord 199. Intrathecal chemotherapy, delivered by ICV infusion or 
lumbar puncture, has been one of the most important treatment modalities to treat TNBC LC. 
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However, no intrathecal chemotherapy agent has consistently demonstrated a superior clinical 
outcome; moreover, intrathecal chemotherapy-associated neurotoxicity has limited its 
application 200,201. In this study, we employed ICV infusions to administer our hiNeuroS-TRAIL 
cells for the treatment of TNBC LC. Our data showed that ICV-infused hiNeuroS-TRAIL cells 
rapidly eliminated the tumor cells in the spine, and no tumor relapse was observed in the 
treatment mice until 6 days after the first death occurred in the control group. On the day of the 
first death in the control group, the average tumor volume in the brains of treated mice was 
reduced by 95%. Moreover, the median survival for the treatment group almost doubled with a 
single dose of ICV-infused therapy. Furthermore, ICV-delivered hiNeuroS therapy has the 
potential not only to treat established LC but even prevent tumor formation. Prophylactic cranial 
irradiation is a well-known prevention strategy for children with acute lymphoblastic leukemia 
202 or patients with small cell lung cancer 203 or aggressive lymphoma 204, which has resulted in a 
decrease of CNS relapse from as high as 66% to only approximately 5% 202,205. By adopting this 
concept of treating tumor cells in the CNS before they can become established metastases, we 
also evaluated our hiNeuroS-TRAIL therapy in a prophylactic setting. We found that with a 
single dose of ICV-infused hiNeuroS-TRAIL cells 7 days before tumor challenge, we were able 
to significantly delay the tumor progression with a 2.8-fold extension of median survival. 
Importantly, leptomeningeal tumor relapse was prevented in both brain and spine in 1/3 of the 
treated mice. While this significant therapeutic effect is observed with only a single dose of a 
single therapeutic agent, tumor rebound was observed in some mice 2 weeks after treatment, 
likely due to the clearance of hiNeuroS-TRAIL cells over time. In the clinic, repeated ICV drug 
infusion has been realized using well-tolerated devices such as the Ommaya reservoir 206. 
Therefore, such devices could also be used for the redosing of hiNeuroS-TRAIL cells in the 
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clinical setting to further improve the long-term therapeutic effect of hiNeuroS-TRAIL-based 
therapy. 
In conclusion, these studies provided strong evidence for the therapeutic potential of a 
second-generation, single factor-reprogrammed iNSC therapy with significantly enhanced 
tumor-homing capability and prolonged persistence. We provide the first evidence showing the 
tumor-homing capability of ICV-infused iNSCs towards TNBC brain parenchymal tumors and 
the significant therapeutic effect of hiNeuroS-TRAIL therapy following ICV infusion. In 
addition, we were also the first to show the potential of ICV-infused iNSCs to treat or prevent 
TNBC LC. While we have employed TRAIL as the monotherapeutic agent delivered by 
hiNeuroS, the hiNeuroS-based delivery system can be expanded to other therapeutic cargos, such 
as nanoparticles, oncolytic viruses, and other gene therapies. Moreover, devices such as the 
Ommaya reservoir enables redosing with multiple therapeutic agents carried by hiNeuroS over 
time to overcome tumor resistance to a single agent. Depending on the chemoattractant secreted 
by the tumor cells, hiNeuroS-based therapy has the potential to treat other types of brain cancer 
besides breast-to-brain metastasis, such as GBM. Our first-generation iNSCs have shown 
significant therapeutic effect in treating GBM with different treatment strategies 1. We believe 
this second-generation therapeutic system with enhanced migratory capability, persistence, and 
proliferating propensity could potentially further improve the therapeutic outcome in GBM 
models. To conclude, hiNeuroS therapy has shown remarkable promise as a future treatment for 




3.4 MATERIALS AND METHODS 
3.4.1 STUDY DESIGN 
This preclinical study explores the potential of developing a second-generation induced 
human neural stem cell (hiNeuroS) cancer therapy using SOX2 single factor mediated cell 
reprogramming system and a neurosphere growth system. We hypothesized that in comparison 
with our first-generation hiNSC, hiNeuroS possessed improved tumor tropism, persistence, and 
therapeutic efficacy against TNBC brain metastases. We used scRNA seq and quantitative PCR 
(qPCR) to characterize hiNeuroS cells and their tumor-homing capabilities at the genetic level. 
hiNeuroS tumor-homing property was also evaluated by both in vitro and in vivo functional tests, 
including in vitro real-time cell migration assay and in vivo tumor homing assay. The tumor 
killing capability of hiNeuroS secreting the cytotoxic protein TRAIL was tested in two different 
TNBC brain metastases animal models, where hiNeuroS-TRAIL was ICV-delivered to treat 
TNBC parenchymal xenograft or to treat or prevent TNBC LC. TNBC brain metastases tumor 
volumes in both treatment and control groups were determined using serial BLI. Brain and spine 
samples were also harvested and sectioned, followed by high resolution imaging to support BLI 
result. In efficacy studies, mice were sacrificed when a mouse displayed signs of distress or lost 
>20% of their maximum weight.  Any BLI points were excluded if signal decreased by more 
than an order of magnitude for only a single time point.  Mice were randomized to treatment or 
control groups, and cages contained mice from multiple groups, blinding the investigator from 
knowing which mice were from treatment vesus control groups. Institutional Aminal Care and 




3.4.2 CELL LINES 
The hTERT-immortalized human fibroblast line NHF-1 was purchased from the University 
of North Carolina at Chapel Hill Tissue Culture Facility. The TNBC brain metastasis cell line 
MDA-MB-231-Br was obtained through material transfer agreement (MTA) (Toshi Yoneda, 
PhD). MDA-MB-231-Br-GFP-NLuc (Nano Luciferase) cells or MDA-MB-231-Br-mCherry-
FLuc (Firefly Luciferase) cells were generated by transducing MDA-MB-231-Br cells with LV-
GFP-NLuc or LV-mCherry-FLuc, resepectively. Both cell lines were cultured in Dulbecco’s 
modified eagle’s medium (DMEM, Gibco) supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS, Millipore), 1% (v/v) Penicillin-Streptomycin (Gibco), and 0.2% (v/v) PlasmocinTM. 
 
3.4.3 HINSC GENERATION 
NHF-1-hTERT human fibroblasts were transdifferentiated, as described previously1.  
Briefly, 1  105 NHF-1-hTERT cells were seeded in six-well plate supplemented with 10% FBS 
DMEM media overnight. The next day (day 0), cells were transduced with LV-GFP-TRAIL, LV-
mCherry-FLuc, or LV-GFP-NLuc for 24 hours in 2% FBS DMEM media supplemented with 
polybrene (8 μg/ml; Thermo Fisher Scientific). The cells were transduced again (day 1) with a 
cocktail of LV-SOX2 and LV-rtTA in 2% FBS DMEM media supplemented with polybrene (8 
μg/ml) for 24 hours. Before use, 1  106 cells were seeded in T-175 flask with regular 10% FBS 
DMEM media overnight. Starting from day 2, cells were cultured in STEMdiff Neural Induction 
Media (STEMCELL Technologies) with doxycycline (2 μg/ml; Sigma-Aldrich) and media was 
replenished every other day. Cells were detached with Accutase cell detachment solution 




3.4.4 HINEUROS GENERATION 
NHF-1-hTERT human fibroblasts were transduced with LV-GFP-TRAIL or LV-mCherry-
FLuc, followed by the cocktail of LV-SOX2 and LV-rtTA by using the same method described 
above. Following transduction, 1  105 cells were seeded in six-well plates with supplemented 
10% FBS DMEM media overnight. Starting from day 2 after the initial transduction, cells were 
cultured in ReNcell NSC Maintenance Medium (Sigma-Aldrich) supplemented with Epidermal 
Growth Factor (EGF; 20 ng/ml; Gemini Bio-Products), Fibroblast Growth Factor (FGF; 20 ng/ml; 
Sigma-Aldrich), and doxycycline (2 μg/ml; Sigma-Aldrich). EGF, FGF, and doxycycline were 
replenished every other day. After 1 to 2 weeks, initial spheres were collected from the media by 
centrifugation, re-seeded to a six-well plate pre-coated with laminin (10mg/ml in PBS, Sigma-
Aldrich) overnight at 37°C, and cultured in supplemented ReNcell medium. Cells were allowed to 
attach to the laminin-coated plate overnight, and the following morning, non-adherent cells were 
washed away with PBS.  Spheres were allowed to regenerate in the supplemented ReNcell 
medium. After floating spheres were formed again, the same sphere collection and re-attachment 
process was repeated thrice before spheres were fully expanded for use. For in vitro and in vivo 
studies, spheres were broken down into a single-cell suspension with Accutase before use.  
 
3.4.5 HINEUROS IMMUNOHISTOCHEMISTRY STAINING 
hiNeuroS-TRAIL or hiNeuroS mCherry-FLuc were collected in 0.7 ml microcentrifuge 
tubes. Spheres were fixed with 10% Neural Buffered Formalin (v/v, Fisherbrand) and 
permeabilized in PBS-T (0.1% v/v Triton X-100, Millipore Sigma-Aldrich) with 1% (w/v) Bolvine 
Serum Albumin (BSA, Sigma-Aldrich). Spheres were then incubated with anti-SOX2 (1:200 v/v, 
Abcam) or anti-Nestin (1:200 v/v, Millipore Sigma) antibodies for 1 hour at room temperature. 
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Spheres were washed with PBS thrice and then incubated with CF555 Goat Anti-Rabbit (1:1000 
v/v, Biotium) or Alexa Fluor 488 Goat Anti-Rabbit (1:1000 v/v, Invitrogen) secondary antibodies 
for 1 hour. After that, spheres were washed with PBS thrice and stained with Hoechst 
(ThermoFisher Scientific™) before being mounted to microscope slides (FisherBiotech™). 
Fluorescent images were acquired with Olympus IX71 fluorescence microscope. Images were 
processed using Fiji ImageJ.  
 
3.4.6 IN VITRO TWO-DIMENSIONAL INSC MIGRATION STUDIES AND ANALYSIS 
Two-chamber cell culture inserts (Ibidi) were placed in 24-well plate pre-coated with 
laminin (10 mg/ml in PBS) overnight at 37°C. A single-cell suspension of 1  104 hiNSC-
mCherry-FLuc or hiNeuroS mCherry-FLuc was seeded on the left side of the insert in 
supplemented Neural Induction Media with 2% FBS or supplemented ReNcell Medium with 2% 
FBS, respectively. 1  104 MB-231-Br-GFP-NLuc or plain NHF-1 cells were seeded on the right 
side of the insert in 2% FBS DMEM. 24 hours after cell seeding, inserts were removed, and wells 
were gently washed with PBS thrice. Then wells were filled with supplemented Neural Induction 
Media or supplemented ReNcell Medium for hiNSC groups and hiNeuroS groups, respectively. 
Cell motion images were acquired at 10X magnification every 2 hours with EVOS FL Auto Cell 
Imaging System (Life Technologies) for 72 hours. Due to the suboptimal adherence of MB231-Br 
cells in Neural Induction Media or ReNcell Medium, the tumor cells closest to the insert edges 
were disrupted during the insert removal and PBS wash steps. While the majority of the tumor 
cells remained, this disruption limited the possibility of capturing the images with both iNSCs and 
tumor cells present in the same 10X field of view. For cell movement tracking analysis, four 
beacons per group were tracked. Within each beacon, 10 hiNSC cells or hiNeuroS cells were 
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randomly selected and their cell migration motion was individually tracked over time (Fiji 
ImageJ). Individual cell motion tracks were plotted, and cell migration directionality, final 
migration displacement, total migration distance, and migration velocity were calculated as 
previously described 129. The number of cells that migrated across the starting line defined by the 
leading hiNSC cell or hiNeuroS cell in each beacon at time 0 was manually counted to determine 
the total number of migrating cells. 
 
3.4.7 IN VITRO HINEUROS-TRAIL TUMOR KILLING ASSAY 
5  103 MB-231-Br-mCh-FLuc cells were seeded in 24-well plate in 10% DMEM. The 
following day, a varying number of hiNeuroS-TRAIL cells were added to the wells with 
different hiNeuroS-TRAIL to MB-231-Br-mCh-FLuc ratio ranging from 20:10 to 1:10. Real-
time images were collected every 2 hours with EVOS FL Auto Cell Imaging System (Life 
Technologies) for 72 hours. The tumor cell viability was measured by quantifying mCherry 
fluorescence signal with Fiji ImageJ. 
 
3.4.8 IN VITRO INSC PROLIFERATION ASSAY 
5  104 hiNSC-mC-FLuc or hiNeuroS-mC-FLuc cells were seeded in 4  12-well plate in 
Neural Induction Media or ReNcell Medium, respectively. To study cell proliferation, serial BLI 
was performed at days 0, 1, 3, and 7. At each time point, 15 μl D-luciferin working solution (15 
mg/ml) was added to each well of one of the four 12-well plates. After 10 min, photon emission 
was measured using the AMI HT system (Spectral Instruments Imaging). BLI data were 




3.4.9 IN VIVO BLI 
To track the tumor growth of MB231-Br-mCherry-FLuc tumor growth or the persistence 
of hiNSC-mCherry-FLuc and hiNeuroS-mCherry-FLuc, serial BLI was performed. Mice were 
administered D-luciferin (3 mg per mouse in 200 μl PBS) by intraperitoneal injection. After 10 
min, photon emission was measured using the AMI HT system. BLI data were analyzed with 
Aura software. 
 
3.4.10 TISSUE PROCESSING 
Following sacrifice, mice were perfused with intracardiac PBS and 10% formalin. Brain 
and/or spine were harvested and incubated in 10% formalin overnight. The next day, samples were 
transferred to 30% sucrose solution for 2 days before being frozen in Optimal Cutting Temperature 
(OCT) media. Brain and spine samples were sectioned using Leica CM1850 cryostat at 12 μm and 
30 μm, respectively. Sectioned tissue samples were collected on microscope slides, stained with 
Hoechst (ThermoFisher Scientific™), and mounted with ProLongTM Gold Antifade Mountant 
(Invitrogen). 
 
3.4.11 IN VIVO INSC TUMOR-HOMING STUDIES FOLLOWING ICV INFUSION 
5  104 MB231-Br-GFP-NLuc cells in 3 μl PBS were implanted in the right hemisphere of 
the brain in athymic nude mice. One week following tumor implantation, a single-cell suspension 
of 5  105 hiNSC-mCherry-FLuc or hiNeuroS-mCherry-FLuc in 5 μl PBS was infused into the left 
ventricle of the mouse brain. The brains of two mice from each group were harvested on days 3, 
7, and 14 after ICV infusion and were processed and sectioned for imaging. Once tumor was visible 
on tissue sectioning, every three slice was collected at thickness of 12 μm with six sections per 
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slide. Fluorescent images were acquired using Olympus IX71 fluorescence microscopy at 10X 
magnification. Representative fluorescence images at different time points were chosen from the 
middle slide for both groups. Images were processed using Fiji ImageJ.  For fluorescence 
quantification and analysis, one sectioned brain sample was chosen from each of the three middle 
slides for each brain sample (n = 3 technical replicates for each animal). Both tumor (GFP) and 
hiNeuroS/hiNSC (mC) fluorescence intensity were quantified, and hiNeuroS/hiNSC-to-tumor 
ratio for fluorescence intensity was then calculated. 
 
3.4.12 IN VIVO INSC PERSISTENCE STUDIES 
A single-cell suspension of 5  105 hiNSC-mCherry-FLuc or hiNeuroS-mCherry-FLuc in 
5 μl PBS were infused into the left ventricle of athymic nude mice brain. To track the persistence 
of infused cells, serial BLI was performed using AMI HT system. 
 
3.4.13 ICV-INFUSED THERAPY STUDIES IN TNBC PM MODEL 
5  104 MB231-Br-mCherry-FLuc cells in 3 μl PBS were implanted in the right hemisphere 
of the brain in athymic nude mice. Three days after tumor implantation, a single-cell suspension 
of 5  105 hiNSC-TRAIL or hiNeuroS-TRAIL in 5 μl PBS was infused into the left ventricle of 
the mouse brain. 5 μl PBS was instead infused for the control group. To track the tumor growth, 
serial BLI was performed using AMI HT system. Mice were sacrificed when body weight dropped 




3.4.14 ICV-INFUSED HINEUROS THERAPY STUDY IN TNBC LEPTOMENINGEAL 
METASTASIS MODEL 
To establish TNBC leptomeningeal metastasis animal model, 2  105 MB231-Br-
mCherry-FLuc cells in 5 μl PBS were implanted to the cisterna magna of athymic nude mice by 
intracisternal injection as previously described 207. 7 days before or 3 days after tumor 
implantation, a single-cell suspension of 5  105 hiNeuroS-TRAIL in 5 μl PBS was infused into 
the left ventricle. Tumor growth in both the mouse brain and spinal cord was monitored by serial 
BLI using the AMI HT system. Mice were sacrificed when body weight dropped by more than 
20%, and survival data were recorded. 2 weeks after tumor implantation, one mouse from each 
group was sacrificed. Mice brain and spine were harvested, processed, and sectioned as 
described above. Fluorescent images were acquired using Olympus IX71 fluorescence 
microscopy and Olympus FV3000RS confocal microscopy. Images were processed with 
Olympus CellSens software.  
 
3.4.15 SCRNA-SEQ STUDY AND ANALYSIS 
scRNA-seq were performed for hiNeuroS-TRAIL, hiNSC-TRAIL, and NHF-1 cells using 
10x Genomics Chromium System in the University of North Carolina at Chapel Hill Advanced 
Analytics Core. Specifically, single-cell suspension of different samples was prepared using 
Accutase Cell Detachment Solution (STEMCELL Technologies). A total of 1777, 3510, and 4357 
cells from hiNeuroS-TRAIL, hiNSC-TRAIL, and NHF-1 cells were captured. To ensure the data 
quality, the genes expressed in less than 3 cells and the cells expressing <= 200 genes were first 
filtered out from each dataset. Furthermore, the cells expressing >= 9000, 6500 and 6000 genes in 
hiNeuroS-TRAIL, hiNSC-TRAIL, and NHF-1 cells, respectively, were considered as putative 
doublets and excluded from the downstream analysis. To compare the three samples, the high-
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quality cells from the three samples were integrated together using Seurat v3 208 to get rid of the 
impact of batch effect. Differentially expressed genes (DEGs) among hiNeuroS-TRAIL, hiNSC-
TRAIL, and NHF-1 cells were detected using the FindMarkers function in Seurat. GO and KEGG 
enrichment analyses were performed for the DEGs using clusterProfiler 209. To further identify 
and characterize the difference in cell manifold among hiNeuroS-TRAIL, hiNSC-TRAIL, and 
NHF-1 cells, trajectory analysis was performed using the integrated data of the three samples in 
Monocle2 210. Genes differentially expressed along the temporal trajectory were identified using 
differentialGeneTest function in Monocle2 with a q-value threshold of 0.05. 
 
3.4.16 REAL-TIME PCR 
The total RNA from hiNeuroS-mC-FLuc, hiNSC-mC-FLuc, and NHF-1 was extracted 
using the PureLink™ RNA Kit (Thermo Fisher Scientific). The expression level of selected genes 
was tested using Custom TaqMan® Array Standard Plate (Thermo Fisher Scientific) and measured 
by QuantStudio 3 (Applied Biosystems). Data analysis was performed on QuantStudio (Thermo 
Fisher Scientific) software.   
 
3.4.17 STATISTICAL ANALYSIS 
Student’s t test was used when only comparing two groups, while one-way analysis of 
variance (ANOVA) was used when comparing more than two groups. For longitudinal studies, 
repeated measure two-way ANOVA analysis was performed. For survival analysis, log-rank 
(Mantel-Cox) test was performed. Data were expressed as means ± SEM. Differences were 






CHAPTER 4: CONCLUSION AND FUTURE DIRECTIONS 
 The rapid development of cell reprogramming strategies has made iNSC a promising 
drug delivery system in the treatment of not only primary brain cancers, such as GBM, but also 
primary peripheral tumors and their brain metastases. This dissertation demonstrated (i) IV-
infused hiNSCs could migrate to TNBC tumors and exert markedly tumor-killing effect, (ii) 
hiNSC-based therapy did not induce toxicity in any major organs following IV infusion, (iii) a 
second-generation iNSC platform, hiNeuroS, with a unique genetic profile and enhanced tumor-
homing capability was developed, (iv) ICV-infused hiNeuroS-based therapy exhibited 
remarkable tumor-killing effect against both TNBC PM and LC.  
 Chapter 2 investigated the use of hiNSCs to treat primary TNBC following IV infusion. 
In vivo cell migration study showed that IV-infused hiNSCs could extravasate out of the 
vasculature and migrate to TNBC tumor foci as early as 3 days after cell administration. While 
hiNSCs were engineered to secret cytotoxic protein TRAIL, it was found that hiNSC-based 
therapy could markedly reduce tumor size and extend survival. In addition, no significant signs 
of toxicity were observed in any of the major organs up to 28 days following the administration 
of hiNSCs or hiNSCs-TRAIL, suggesting a safe profile of hiNSC-based therapy. Together, these 
data demonstrated the efficacy and safety of using hiNSCs as a systemic therapy in treating 
primary TNBC. 
 In Chapter 3, a second-generation iNSC, hiNeuroS, was developed using SOX2 single 
factor-mediated cell reprogramming strategy and neurosphere-based culturing system. In 
comparison with the first-generation iNSCs, hiNeuroSs possessed enhanced stemness and tumor 
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tropism-related gene expression profile, and tumor-homing capability towards TNBC brain 
metastasis following ICV infusion. When tested in TNBC PM model, ICV-infused TRAIL-
releasing hiNeuroSs could significantly reduce tumor burden and extend median survival by 
50%. For treating TNBC LC, hiNeuroS-based therapy was investigated as either established 
tumor treatment or prophylactic treatment. The results showed that hiNeuroS-based therapy 
delivered by ICV significantly suppressed tumor growth and delayed tumor progression in the 
established tumor model and prophylactic tumor model, respectively. Remarkable extended 
survival was also observed with both treatment strategies. Together, these studies demonstrated 
the therapeutic potential of ICV-delivered hiNeuroS-based therapy in the treatment of TNBC 
brain metastases.  
 To further bring these promising iNSC-based cancer therapies to the clinic, future 
research should focus on the following several aspects.  
First, both the therapeutic effect and safety of iNSC-based cancer therapies should be 
further evaluated in immunocompetent mouse models. As previously mentioned, the major 
advantage of personalized cell therapy is its autologous property that could minimize immune 
response against the administered cells while maximizing the therapeutic outcome. However, to 
date, all of the iNSC-based cancer therapy-related studies were conducted in 
immunocompromised mouse models due to the need of using human tumor cell lines, which is 
one of the major limitations of our studies making the therapy evaluation incomplete by missing 
out on the immune component.  Therefore, as an immediate next step, iNSC-based cancer 
therapies should be characterized in humanized immunocompetent models, such as hu-PBL 




Second, the development of iNSCs loaded with a broader range of therapeutic cargos is 
desired. Tumor tropism is one of the key properties that make iNSC-based cancer therapy 
appealing in treating cancers as it has been shown that iNSCs could rapidly track down the 
tumors with different administration routes. When iNSCs arrive at the tumor foci, it is the 
therapeutic cargos that execute the tumor-killing. TRAIL and TK are the two most commonly 
investigated therapeutic cargos. However, due to the differences in tumor properties for different 
tumor types, as well as the nature of tumor heterogeneity, a wide variety of therapeutic agents 
will be needed to fully eradicate the tumor. For instance, depending on the tumor and its 
microenvironment properties, different cytotoxic proteins and immunomodulating agents can 
result in completely different therapeutic outcomes. Thus, developing an iNSC-based platform 
therapy equipped with modulized and personalized therapeutic agents will further advance the 
potential clinical application of iNSC-based therapies in treating cancers.  
Third, studies investigating the effect of a combination treatment consisting of iNSC-
based cancer therapy and emerging cancer therapy should be explored. As more and more novel 
cancer therapies get FDA approval (e.g. PD-1/PD-L1 antibodies), it is important to investigate 
the potential synergic effect between iNSC-based cancer therapy and these emerging therapies to 
maximize the clinical outcome for patients.  
Last, a more robust cell production and quality control process needs to be established. 
Based on our scRNA-seq analysis, the generated hiNeruoSs were a heterogeneous cell 
population with some of the cells possessed a more preferred genetic profile than the others. To 
ensure the uniformity and high quality of the generated iNSCs, strategies to optimize the end-to-
end cell production process are highly desired. One of the strategies could be to purify the cell 
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product after each cell manufacturing step through fluorescence-activated cell sorting (FACS) 
based on the desired cell surface markers of the target cell population.  
Overall, this dissertation demonstrated the prominent potential of using iNSC-based 





APPENDIX A: SUPPLEMENTARY FIGURES FOR INVESTIGATION OF IV-INFUSED 
HINSC-BASED CANCER THERAPY 
 
 









Appendix A.2. BLI images of representative mice with and without orthotopic A549 tumors infused 











Appendix A.3. hiNSC in vitro killing against individual replicates of H460 and MDA-MB231-Br. (A) 
Logarithmic scale of raw luminescence values for each replicate of H460-mC-FLuc with varying ratios of 
H460:hiNSC-TRAIL over time. (B) Logarithmic scale of raw luminescence values for each replicate of MDA-MB-




Appendix A.4. Therapeutic efficacy of hiNSC-TRAIL cells for individual mice with H460 or MDA-MB231-Br 
tumors. (A) Bioluminescence of H460-mC-FLuc tumors in individual mice infused intravenously with control 
(hiNSC-GFP, N = 15) or therapeutic (hiNSC-TRAIL, N =16). (B) Bioluminescence of MDA-MB231-Br-mC-FLuc 
tumors in individual mice infused intravenously with control (hiNSC-GFP, N = 4) or therapeutic (hiNSC-TRAIL, N 
= 5). (C) Volume of visible MDA-MB231-Br-mC-FLuc tumors in mice infused with hiNSC-GFP or therapeutic 
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Appendix A.5. Viability of non-tumorous cells with exposure to TRAIL. A) Viability of hiNSC-GFP-Fluc cells 
with addition of TRAIL protein. B) Viability of NHF1-mC-Fluc-S/R with additional of TRAIL protein. Data 
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APPENDIX B: SUPPLEMENTARY FIGURES FOR THE DEVELOPMENT OF NEXT-
GENERATION INSC TO TREAT TNBC BRAIN METASTASES  






Appendix B.2. Merged channel images (fluorescent and bright field) showing hiNeuroS in vitro migration with 

















Appendix B.3. Fluorescent images of brain cross-sections showing the presence of hiNSC (red) at tumor foci 
(green) at different time points after ICV infusion. Scale bar = 100 μm 
 
Appendix B.4. hiNeuroS and hiNSC long-term persistence in vivo following ICV infusion. (A) Representative 
BLI images showing in vivo persistence of hiNeuroS and hiNSC following ICV infusion. (B) Quantification of ICV-
infused hiNeuroS or hiNSC BLI signal in vivo over time in normal scale. (C) Quantification of ICV-infused hiNeuroS 
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Appendix B.5. Fluorescent images of MB231-Br cells treated with various ratios of hiNeuroS-TRAIL cells over 
time in vitro. Scale bar = 100 μm 
 
 























































Appendix B.7. MB231-Br tumor BLI images of prophylactic treatment and established tumor treatment 




Appendix B.8. Both (A) brain and (B) spine tumor BLI signal of each individual mouse treated with ICV-













































































Appendix B.9. Fold change in hiNeuroS and hiNSC bioluminescence intensity during 7 days culturing in vitro. 
n = 6 technical replicates.  
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